UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED ~~JUNE 30~~DECEMBER 31, 2022

Commission File Number 000-56112

GENUFOOD ENERGY ENZYMES CORP.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

1108 S. Baldwin Avenue, Suite 107

Arcadia, California 91007

(Address of principal executive offices, including zip code.)

(855) 707-2077

(Telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
N/A		N/A		N/A

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☒☐ NO ☐☒

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 299,686,921 shares as of ~~August~~February 1013, ~~2022~~2023

GENUFOOD ENERGY ENZYMES CORP.

FORM 10-Q FOR THE THREE- ~~AND NINE-~~MONTH PERIOD ENDED DECEMBER ~~JUNE 30~~31, 2022

TABLE OF CONTENTS

		Page Number
	PART I. FINANCIAL INFORMATION
ITEM 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	1
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	1213
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	1918
ITEM 4.	CONTROLS AND PROCEDURES	1918
	PART II. OTHER INFORMATION	20
ITEM 1.	LEGAL PROCEEDINGS	2120
ITEM 1A.	RISK FACTORS	2120
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	2120
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	2120
ITEM 4.	MINE SAFETY DISCLOSURES	2120
ITEM 5.	OTHER INFORMATION	2120
ITEM 6.	EXHIBITS	2221

~~PART~~ITEM 1. ICONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~FINANCIAL~~GENUFOOD ~~INFORMATION~~ENERGY ENZYMES CORPORATION

~~ITEM~~CONDENSED 1.CONSOLIDATED ~~FINANCIAL~~BALANCE ~~STATEMENTS~~SHEETS

GENUFOOD ENERGY ENZYMES CORPORATION

	December 31,			September 30,
	2022			2022
ASSETS	(Unaudited)
CURRENT ASSETS
Cash and cash equivalents	$	46,526		$	136,400
Prepayment		6,657			14,493
Total Current Assets		53,183			150,893

Equipment		15,005			-

Total Assets	$	68,188		$	150,893

LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Accounts payable	$	118,471		$	102,185
Due to related parties		134,213			102,831
Total Current Liabilities		252,684			205,016

Commitment and contingencies (Note 9)		29,976			29,226

STOCKHOLDERS’ DEFICIT
Common stock; $0.001 par value; 10,000,000,000 shares authorized; 299,686,921 and 299,686,921 shares issued and outstanding as of December 31, 2022 and September 30, 2022 respectively		299,687			299,687
Additional paid-in capital		17,050,058			16,975,058
Discount on common stock		(7,241,581	)		(7,241,581	)
Accumulated other comprehensive loss		(193,643	)		(193,558	)
Accumulated deficit		(10,128,993	)		(9,922,955	)
Total Stockholders’ Deficit		(214,472	)		(83,349	)

Total Liabilities and Stockholders’ Deficit	$	68,188		$	150,893

~~CONDENSED CONSOLIDATED BALANCE SHEETS~~1

	As of			As of
	June 30,			September 30,
	2022			2021
	(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	211,145		$	9,271
Prepayment		21,667			25,773
Total Current Assets		232,812			35,044
Investment		-			350,000
Total Assets	$	232,812		$	385,044
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable	$	97,025		$	100,746
Accrued expenses		-			1,590
Due to related parties		86,998			3,010
Total Current Liabilities		184,023			105,346
Commitment and contingencies (Note 8)		28,476			26,226
STOCKHOLDERS’ EQUITY
Common stock; $0.001 par value; 10,000,000,000 shares authorized; 299,686,921 and 299,686,921 shares issued and outstanding as of June 30, 2022 and September 30, 2021, respectively		299,687			299,687
Additional paid-in capital		16,911,770			16,911,770
Discount on common stock		(7,241,581	)		(7,241,581	)
Accumulated other comprehensive loss		(193,595	)		(193,583	)
Accumulated deficit		(9,755,968	)		(9,522,821	)
Total Stockholders’ Equity		20,313			253,472
Total Liabilities and Stockholders’ Equity	$	232,812		$	385,044

GENUFOOD ENERGY ENZYMES CORPORATION

1CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

~~GENUFOOD ENERGY ENZYMES CORPORATION~~(UNAUDITED)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	For the Three Months Ended December 31,
	2022			2021
REVENUE	$	-		$	-

OPERATING EXPENSES
General and administrative expenses		205,245			103,340
Total operating expenses		205,245			103,340

LOSS FROM OPERATIONS		(205,245	)		(103,340	)

OTHER INCOME (EXPENSE)
Interest income (expense)		-			1
Foreign currency (loss) income		(43	)		2
Other non-operating income (expenses), net		(750	)		(750	)
Total other expense		(793	)		(747	)

Loss before income taxes		(206,038	)		(104,087	)

Income tax expense		-			-

NET LOSS	$	(206,038	)	$	(104,087	)

OTHER COMPREHENSIVE LOSS
Foreign currency transaction adjustment		(85	)		(8	)

COMPREHENSIVE LOSS	$	(206,123	)	$	(104,095	)

BASIC AND DILUTED LOSS PER SHARE	$	*		$	*

WEIGHTED AVERAGE NUMBER OF COMMON STOCKS-BASIC AND DILUTED		299,686,921			299,686,921

~~(UNAUDITED)~~* Less than $0.01 per share

	For the Three Months Ended June 30,						For the Nine Months Ended June 30,
	2022			2021			2022			2021
REVENUE	$	-		$	-		$	-		$	-
OPERATING EXPENSES
General and administrative expenses		65,091			98,941			230,516			262,516
Total operating expenses		65,091			98,941			230,516			262,516
LOSS FROM OPERATIONS		(65,091	)		(98,941	)		(230,516	)		(262,516	)
OTHER INCOME (EXPENSE)
Interest income (expense)		2			(41	)		5			(1,734	)
Foreign currency income (loss)		-			(69	)		6			(511	)
Other non-operating income (expenses), net		(747	)		65,006			(2,642	)		66,588
Total other (expense) income		(745	)		64,896			(2,631	)		64,343
Loss before income taxes		(65,836	)		(34,045	)		(233,147	)		(198,173	)
Income tax expense		-			-			-			800
NET LOSS	$	(65,836	)	$	(34,045	)	$	(233,147	)	$	(198,973	)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency transaction adjustments		(10	)		(320	)		(12	)		(1,820	)
COMPREHENSIVE LOSS	$	(65,846	)	$	(34,365	)	$	(233,159	)	$	(200,793	)
BASIC & DILUTED LOSS PER SHARE	$	*		$	*		$	*		$	*
WEIGHTED AVERAGE NUMBER OF ORGINARY SHARES-BASIC & DILUTED		299,686,921			230,622,703			299,686,921			189,356,789

*GENUFOOD ~~Less~~ENERGY ~~than~~ENZYMES ~~$0.01 per share~~CORPORATION

2CONDENSED CONSOILDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY

~~GENUFOOD ENERGY ENZYMES CORPORATION~~(UNAUDITED)

CONDENSED CONSOILDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

	Common Stock				Additional		Discount on						Accumulated Other			Total
	Number of				Paid-in-		common			Accumulated			Comprehensive			Stockholders’
	Shares		Amount		Capital		stock			Deficit			Income (loss)			Deficit
BALANCE AT SEPTEMBER 30, 2022		299,686,921	$	299,687	$	16,975,058	$	(7,241,581	)	$	(9,922,955	)	$	(193,558	)	$	(83,349	)
Stock-based compensation		-		-		75,000		-			-			-			75,000
Foreign currency translation		-		-		-		-			-			(85	)		(85	)
Net loss		-		-		-		-			(206,038	)		-			(206,038	)
BALANCE AT DECEMBER 31, 2022		299,686,921	$	299,687	$	17,050,058	$	(7,241,581	)	$	(10,128,993	)	$	(193,643	)	$	(214,472	)

FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2022 AND 2021

	Common Stock				Additional		Discount on						Accumulated Other			Total
	Number of				Paid-in-		stock			Accumulated			Comprehensive			Stockholders’
	Shares		Amount		Capital		common			Deficit			Income (loss)			Equity
BALANCE AT SEPTEMBER 30, 2021		299,686,921	$	299,687	$	16,911,770	$	(7,241,581	)	$	(9,522,821	)	$	(193,583	)	$	253,472
Foreign currency translation		-		-		-		-			-			(8	)		(8	)
Net loss		-		-		-		-			(104,087	)		-			(104,087	)
BALANCE AT DECEMBER 31, 2021		299,686,921	$	299,687	$	16,911,770	$	(7,241,581	)	$	(9,626,908	)	$	(193,591	)	$	149,377

~~(UNAUDITED)~~3

													Accumulated
	Common Stock				Additional		Discount on						Other			Total
	Number of				Paid-in-		common			Accumulated			Comprehensive			Stockholders'
	Shares		Amount		Capital		stock			Deficit			Income (loss)			Equity
BALANCE AT MARCH 31, 2022		299,686,921	$	299,687	$	16,911,770	$	(7,241,581	)	$	(9,690,132	)	$	(193,585	)	$	86,159
Foreign Currency Translation adjustment														(10	)		(10	)
Net Loss											(65,836	)					(65,836	)
BALANCE AT JUNE 30, 2022		299,686,921	$	299,687	$	16,911,770	$	(7,241,581	)	$	(9,755,968	)	$	(193,595	)	$	20,313

GENUFOOD ENERGY ENZYMES CORPORATION

													Accumulated
	Common Stock				Additional		Discount on						Other			Total
	Number of				Paid-in-		common			Accumulated			Comprehensive			Stockholders'
	Shares		Amount		Capital		stock			Deficit			Income (loss)			Equity
BALANCE AT MARCH 31, 2021		217,483,085	$	217,483	$	16,180,125	$	(7,241,581	)	$	(8,323,317	)	$	(193,535	)	$	639,175
Issuance of Common Stock for Debt Conversion – Promissory Note Including Interest		3,059,836		3,060		27,538											30,598
Shares Issued for Cash		63,000,000		63,000		559,770											622,770
Foreign Currency Translation adjustment														(320	)		(320	)
Net Loss											(34,045	)					(34,045	)
BALANCE AT JUNE 30, 2021		283,542,921	$	283,543	$	16,767,433	$	(7,241,581	)	$	(8,357,362	)	$	(193,855	)	$	1,258,178

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

3(UNAUDITED)

GENUFOOD ENERGY ENZYMES CORPORATION

	For the Three Months Ended December 31,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(206,038	)	$	(104,087	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		75,000			-
Change in operating assets and liabilities:
Prepayment		7,836			7,406
Accounts payable		17,401			(3,337	)
Accrued expenses		-			(851	)
Due to related parties		30,182			28,581
Commitment and contingencies		750			750
Net cash used in operating activities		(74,869	)		(71,538	)

CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of Hukui investment		-			350,000
Purchase of equipment		(15,005	)		-
Net cash (used in) provided by financing activities		(15,005	)		350,000

EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		-			-

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(89,874	)		278,462

CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		136,400			9,271

CASH AND CASH EQUIVALENTS - END OF PERIOD	$	46,526		$	287,733

SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

~~CONDENSED CONSOILDATED STATEMENTS OF STOCKHOLDERS’ EQUITY~~4

~~FOR THE THREE AND NINE MONTHS ENDED JUNE 30,~~GENUFOOD ~~2022~~ENERGY ~~AND~~ENZYMES ~~2021~~CORP

~~(UNAUDITED)~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

													Accumulated
	Common Stock				Additional		Discount on						Other			Total
	Number of				Paid-in-		common			Accumulated			Comprehensive			Stockholders'
	Shares		Amount		Capital		stock			Deficit			Income (loss)			Equity
BALANCE AT SEPTEMBER 30, 2021		299,686,921	$	299,687	$	16,911,770	$	(7,241,581	)	$	(9,522,821	)	$	(193,583	)	$	253,472
Foreign Currency Translation adjustment														(12	)		(12	)
Net Loss											(233,147	)					(233,147	)
BALANCE AT JUNE 30, 2022		299,686,921	$	299,687	$	16,911,770	$	(7,241,581	)	$	(9,755,968	)	$	(193,595	)	$	20,313

(UNAUDITED)

													Accumulated
	Common Stock				Additional		Discount on						Other			Total
	Number of				Paid-in-		common			Accumulated			Comprehensive			Stockholders'
	Shares		Amount		Capital		stock			Deficit			Income (loss)			Equity
BALANCE AT SEPTEMBER 30, 2020		104,083,120	$	104,083	$	15,134,979	$	(7,241,581	)	$	(8,158,389	)	$	(192,035	)	$	(352,943.00	)
Shares Issued for Cash – December 2020		107,000,000		107,000		957,148											1,064,148
Shares Issued for Cash – June 2021		63,000,000		63,000		559,770											622,770
Issuance of Common Stock for Debt Conversion – Director and Officers		5,121,889		5,122		70,972											76,094
Issuance of Common Stock for Debt Conversion – Consultants		1,278,076		1,278		17,026											18,304
Issuance of Common Stock for Debt Conversion – Promissory Note Including Interest		3,059,836		3,060		27,538											30,598
Foreign Currency Translation adjustment														(1,820	)		(1,820	)
Net Loss											(198,973	)					(198,973	)
BALANCE AT JUNE 30, 2021		283,542,921	$	283,543	$	16,767,433	$	(7,241,581	)	$	(8,357,362	)	$	(193,855	)	$	1,258,178

NOTE 1 – GENERAL ORGANIZATION AND BUSINESS

4Genufood Energy Enzymes Corp., USA (the “Company” or “GEEC”) was incorporated under the laws of the State of Nevada on June 21, 2010. On February 13, 2012, GEEC incorporated a wholly-owned subsidiary, Genufood Enzymes (S) Pte Ltd (“GESPL”) in Singapore, which ceased its operations on January 9, 2023.

~~GENUFOOD~~Since ~~ENERGY~~its inception, ~~ENZYMES~~the ~~CORPORATION~~Company has always been in the development stage and never generated significant revenues. The Company is currently developing business in Electric Vehicle Charge station. The Company has engaged in business agreements and development with various parties. During the three months ended December 31, 2022, the Company has initiated its electric vehicle charging station business.

~~CONDENSED~~The ~~CONSOLIDATED~~Company made ~~STATEMENTS~~two OFinvestments ~~CASH~~in ~~FLOWS~~Hukui Biotechnology Corporation (“Hukui”) by purchasing 80,000 shares of Hukui’s Series C Preferred Stock for $800,000 on December 15, 2020; and purchasing 60,000 shares of Hukui’s Series C Preferred Stock for $600,000 on June 25, 2021. The Company, an individual and resident of the Republic of China (the “Purchaser”), and Hukui, entered into a Stock Purchase Agreement dated as of November 17, 2021, pursuant to which the Company agreed to sell these 140,000 shares of Hukui’s Series C Preferred Stock (the “Hukui Shares”) to the Purchaser for $350,000 in cash, or $2.50 per share. The sale of the Hukui Shares closed on November 19, 2021.

On August 1, 2022, the board of directors (~~UNAUDITED~~the “Board”) of the Company unanimously approved to expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

	For the Nine Months Ended
	June 30,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(233,147	)	$	(198,973	)
Adjustments to reconcile net loss to net cash used in operating activities:
Commitment and contingencies		2,250			-
Change in operating assets and liabilities:
Prepayment		4,106			(390	)
Accounts payable		(3,692	)		1,564
Accrued expenses		(1,590	)		5,316
Due to related parties		83,988			6,078
Net cash used in operating activities		(148,085	)		(186,405	)
CASH FLOWS FROM INVESTING ACTIVITIES
Payment for Hukui investment		-			(1,400,000	)
Proceeds from sale of Hukui investment		350,000			-
Net cash provided by (used in) financing activities		350,000			(1,400,000	)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of notes payable – related party		-			(120,410	)
Proceeds from issuance of promissory note		-			30,000
Proceeds from issuance of common stock		-			1,686,918
Net cash provided by financing activities		-			1,596,508
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		(41	)		48
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		201,874			10,151
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		9,271			18,092
CASH AND CASH EQUIVALENTS - END OF PERIOD	$	211,145		$	28,243
SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION
Cash paid for interest	$	-		$	2,271
Cash paid for income taxes	$	-		$	800
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of Common Stock for Debt Conversion – Director and Officers	$	-		$	76,094
Issuance of Common Stock for Debt Conversion – Consultants		-			18,304
Issuance of Common Stock for Debt Conversion – Promissory Note		-			30,000
Issuance of Common Stock for Debt Conversion – Promissory Note Interest		-			598
Total	$	-		$	124,996

On October 26, 2022, the Company entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow the Company to install its electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, the Company has agreed to share the revenue generated by the sales of electricity at the Charging Stations with the Site Hosts in accordance with the schedules set forth therein.

5As of December 31, 2022, the Company has purchased certain electric vehicle charging equipment. Furthermore, the Company is in the process of obtaining permits to construct the Charging Stations at the three confirmed sites. As of December 31, 2022, the Company contracted an architectural firm on providing designing and engineering services for two sites, and working on technical issues for the third site.

~~GENUFOOD~~As ~~ENERGY~~of ~~ENZYMES~~February ~~CORP~~13, 2023, the Company has received the finalized site plans and electrical diagrams from the architectural firm and electrical engineers for 2 sites. The Company has also received permission from the site owners to proceed with the charging station construction permit applications with the local municipalities.

~~NOTES~~NOTE 2 TO– ~~CONDENSED~~SUMMARY ~~CONSOLIDATED~~OF ~~FINANCIAL~~SIGNIFICANT ~~STATEMENTS~~ACCOUNTING POLICIES

~~(UNAUDITED)~~Basis of Presentation

~~NOTE~~The 1Company’s condensed –consolidated ~~GENERAL~~financial ~~ORGANIZATION~~statements ~~AND~~have ~~BUSINESS~~been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”). The accompanying condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair statement of the results of operations for the periods shown and are not necessarily indicative of the results to be expected for the full year ending September 30, 2023. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2022.

~~Genufood Energy~~Principle ~~Enzymes Corp., USA (the “Company” or “GEEC”) was incorporated under the laws~~ of ~~the State of Nevada on June 21, 2010. On February 13, 2012, GEEC incorporated a wholly-owned subsidiary company, Genufood Enzymes (S) Pte Ltd (“GESPL”) in Singapore.~~Consolidation

The ~~Company~~condensed isconsolidated ~~currently~~financial astatements ~~shell~~include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The wholly-owned subsidiary of the Company did not have business activities during the three months ended December 31, 2022 and 2021.

~~Since~~Use its inception, the Company has always been in the development stage and never generated significant revenues. At this time, the Company does not have any specific plan to commence any particular new business. The Company’s focus will be to consider either or both of a ~~possible business combination, which may include but not be limited to a reverse merger, with another operating business, or commencing a business of its own.~~Estimates

The ~~Company~~preparation ~~made~~of ~~two~~the ~~investments~~condensed inconsolidated ~~Hukui~~financial ~~Biotechnology~~statements ~~Corporation~~in ~~(“Hukui”)~~conformity bywith ~~purchasing~~US ~~80,000~~GAAP ~~shares~~requires ofmanagement ~~Hukui’s~~to ~~Series~~make Cestimates ~~Preferred Stock~~and ~~for~~assumptions ~~$800,000~~that affect onthe ~~December~~reported ~~15,~~amounts ~~2020;~~of assets and ~~purchasing~~liabilities ~~60,000~~and ~~shares~~disclosure of ~~Hukui’s~~contingent ~~Series~~assets ~~C Preferred Stock for $600,000 on June 25, 2021. The Company, an individual~~ and ~~resident~~liabilities ofat the ~~Republic~~date of ~~China (~~the ~~“Purchaser”), and Hukui, entered into a Stock~~consolidated ~~Purchase~~financial ~~Agreement~~statements ~~dated~~and ~~as of November 17, 2021, pursuant to which~~ the ~~Company~~reported ~~agreed~~amounts ~~to sell these 140,000 shares~~ of ~~Hukui’s~~revenues ~~Series C~~and ~~Preferred~~expenses ~~Stock~~during (the ~~“Hukui~~reporting ~~Shares”) to the Purchaser for $350,000 in cash, or $2~~period.50 ~~per~~Actual ~~share.~~results ~~The~~could ~~sale~~differ offrom ~~the Hukui Shares~~those ~~closed on November 19, 2021~~estimates.

~~NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES~~5

~~Basis~~GENUFOOD ofENERGY ~~Presentation~~ENZYMES CORP NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~The Company’s condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America~~ (~~“US GAAP”~~UNAUDITED). The accompanying condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair statement of the results of operations for the periods shown and are not necessarily indicative of the results to be expected for the full year ending September 30, 2022. These condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2021.

~~Principle~~ Concentrations of ~~Consolidation~~Credit Risk

~~The~~Financial instruments ~~condensed~~that ~~consolidated~~potentially ~~financial~~subject ~~statements include~~ the ~~accounts~~Company to significant concentrations of ~~GEEC~~credit ~~and~~risk ~~its~~consisted ~~wholly-owned~~primarily ~~subsidiary~~of ~~GESPL.~~cash, ~~All~~to ~~significant~~the ~~inter-company~~extent balances ~~accounts~~exceeded ~~and~~limits ~~transactions~~that ~~have~~were ~~been eliminated~~insured inby ~~consolidation.~~the ~~The~~Federal ~~wholly-owned~~Deposit ~~subsidiary~~Insurance ofCorporation. ~~the~~The Company ~~did~~does not ~~have~~require ~~business~~collateral ~~activities~~and ~~during~~maintains reserves ~~the~~for ~~nine~~potential ~~months~~credit ~~ended June~~losses. ~~30,~~Such ~~2022~~losses have historically been immaterial and ~~2021~~have been within management’s expectations.

~~Use~~Cash and ofCash ~~Estimates~~Equivalents

The ~~preparation~~Company considers ofall ~~the~~highly ~~consolidated~~liquid ~~financial statements~~instruments ~~in conformity~~ with USoriginal ~~GAAP~~maturities ~~requires~~of ~~management~~three tomonths ~~make~~or ~~estimates~~less ~~and~~when ~~assumptions~~acquired ~~that~~to ~~affect~~be ~~the~~cash ~~reported~~equivalents. ~~amounts~~As of ~~assets~~December ~~and~~31, ~~liabilities~~2022 and ~~disclosure~~September of30, ~~contingent~~2022, ~~assets and liabilities at~~ the ~~date~~Company ofdid ~~the~~not ~~consolidated~~have ~~financial~~cash ~~statements and the reported amounts of revenues and expenses during the reporting period~~equivalents. ~~Actual~~The ~~results~~Company’s ~~could~~cash ~~differ~~was ~~from~~denominated ~~those~~in ~~estimates.~~United ~~For the nine months ended~~States ~~June~~Dollars ~~30,~~(“USD”) ~~2022~~or ~~and~~New ~~2021,~~Taiwan noDollars ~~significant~~(“TWD”) ~~estimates~~ and ~~assumptions~~was ~~have~~placed ~~been~~with ~~made~~banks in the ~~consolidated~~United ~~financial~~States ~~statements~~of America and Taiwan.

6Fair Value of Financial Instruments

~~Concentrations~~The Company follows the guidance of ~~Credit~~the ~~Risk~~ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

~~Financial~~● ~~instruments~~Level ~~that~~1 ~~potentially~~inputs ~~subject the~~are ~~Company~~quoted toprices ~~significant~~available ~~concentrations~~for ofidentical ~~credit~~assets ~~risk~~and ~~consisted~~liabilities ~~primarily~~in ofactive ~~cash,~~markets. to● ~~the~~Level ~~extent~~2 ~~balances~~inputs ~~exceeded~~are ~~limits~~observable ~~that~~for ~~were insured~~the byasset ~~the~~or ~~Federal~~liability, ~~Deposit~~either ~~Insurance~~directly ~~Corporation.~~or ~~The~~indirectly, ~~Company~~including ~~does~~quoted ~~not~~prices ~~require~~for ~~collateral~~similar assets and ~~maintains~~liabilities ~~reserves~~in ~~for~~active ~~potential~~markets ~~credit losses~~or other inputs that are observable or can be corroborated by observable market data. ~~Such~~● ~~losses~~Level ~~have~~3 ~~historically~~inputs ~~been~~are ~~immaterial~~less observable and ~~have~~reflect ~~been~~our ~~within~~own ~~management’s expectations~~assumptions.

~~Cash~~The Company’s financial instruments consist principally of cash and ~~Cash~~cash ~~Equivalents~~equivalents, accounts payable and accrued expenses and due to related parties. The carrying amounts of such financial instruments in the accompanying consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.

~~The Company considers~~Foreign ~~all~~Currency ~~highly~~Translation ~~liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of June 30, 2022~~ and September 30, 2021, the Company did not have cash equivalents. The Company’s cash was denominated in United States Dollars (“USD”) or New Taiwan Dollars (“TWD”) and was placed with banks in the United States of America and Taiwan.Transactions

~~Fair~~The ~~Value~~reporting and functional currency of ~~Financial~~GEEC ~~Instruments~~is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar (“SGD”).

~~The~~For ~~Company~~financial reporting ~~follows~~purposes, the ~~guidance~~financial statements of the ~~ASC~~Company’s ~~Topic~~Singapore subsidiary, which are prepared using the SGD, are translated ~~820-10~~into the Company’s reporting currency, ~~“Fair~~USD. Assets ~~Value~~and ~~Measurements~~liabilities are translated using the exchange rate on the balance sheet date, which was 0.7464 and ~~Disclosures”~~0.6970 ~~(“ASC~~as ~~820-10”)~~of December 31, ~~with~~2022 ~~respect~~and toSeptember ~~financial~~30, ~~assets~~2022, respectively. Revenue and ~~liabilities that~~expenses are ~~measured~~translated atusing average ~~fair~~exchange ~~value~~rates prevailing during each reporting period. The 0.7214 and 0.7370 average ~~ASC~~exchange ~~820-10~~rates were ~~establishes~~used ato translate revenues and expenses for the three~~-tier~~ ~~fair~~months ~~value~~ended ~~hierarchy~~December ~~that~~31, ~~prioritizes~~2022 and 2021, respectively. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the ~~inputs~~translation ~~used~~are inrecorded ~~measuring~~as a separate component of ~~fair~~accumulated ~~value~~other ascomprehensive ~~follows:~~loss in stockholders’ deficit.

●Transactions denominated ~~Level~~in 1currencies ~~inputs~~other ~~are~~than ~~quoted~~the ~~prices~~functional ~~available~~currency ~~for~~are ~~identical~~translated ~~assets~~into ~~and~~the ~~liabilities~~functional incurrency ~~active~~at ~~markets.~~the ●exchange ~~Level~~rates 2prevailing at ~~inputs~~the ~~are~~dates ~~observable~~of ~~for~~ the ~~asset~~transactions. orThe ~~liability,~~resulting ~~either~~exchange ~~directly or indirectly~~difference, ~~including~~presented ~~quoted~~as ~~prices~~foreign ~~for~~currency ~~similar~~transaction ~~assets~~loss, ~~and~~is ~~liabilities~~included in ~~active~~the accompanying ~~markets~~condensed orconsolidated ~~other~~statements ~~inputs~~of ~~that are observable or can be corroborated by observable market data~~operations. ~~● Level 3 inputs are less observable and reflect our own assumptions.~~

The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses, due to related parties, and notes payable. The carrying amounts of such financial instruments in the accompanying condensed consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.6

~~Foreign~~GENUFOOD ~~Currency~~ENERGY ~~Translation~~ENZYMES CORP NOTES ~~and~~TO ~~Transactions~~CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~The reporting and functional currency of GEEC is the USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the Singapore Dollar~~ (~~“SGD”~~UNAUDITED).

~~For financial~~Business reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.7195 and 0.7368 as of June 30, 2022 and September 30, 2021, respectively. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7341 and 0.7480 average exchange rates were used to translate revenues and expenses for the nine months ended June 30, 2022 and 2021, respectively. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ equity.Segments

~~Transactions denominated~~The ~~in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing~~Company atoperates ~~the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction loss, is included~~ in ~~the accompanying consolidated statements of operations~~only one segment.

7Net Income (Loss) Per Share

~~Business~~The ~~Segments~~Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the three months ended December 31, 2022 and 2021.

~~The~~Discounts on ~~Company~~Common ~~operates in only one segment.~~Stock

~~Net~~Common ~~Income~~stock issued ~~(Loss)~~lower ~~Per~~than ~~Share~~the Company’s par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s condensed consolidated financial statements.

~~The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by the weighted~~Stock-~~average number~~Based of common shares outstanding during the period. Diluted income per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the nine months ended June 30, 2022 and 2021.Compensation

~~Discounts~~The onCompany accounts ~~Common~~for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

~~Common stock issued lower than the Company’s~~Income par value is treated as common stock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s condensed consolidated financial statements.Taxes

~~Stock-Based~~Income ~~Compensation~~taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.

The Company ~~accounts~~considers ~~for~~positive and negative evidence when determining whether a portion or all of its ~~stock-based~~deferred ~~compensation~~tax inassets ~~which~~will more likely than not be realized. This assessment considers, among other matters, the ~~Company~~nature, ~~obtains~~frequency ~~employee~~and ~~services~~severity inof ~~share-based~~current ~~payment~~and ~~transactions~~cumulative ~~under~~losses, ~~FASB~~forecasts ~~ASC~~of ~~Topic~~future ~~718~~profitability, ~~Compensation~~the –duration ~~Stock~~of ~~Compensation~~statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which ~~requires~~the temporary differences become deductible. When assessing the ~~Company~~realization toof ~~expense~~deferred tax assets, the ~~cost~~Company has considered possible sources of ~~employee~~taxable ~~services~~income ~~received~~including in(i) future ~~exchange~~reversals ~~for~~of anexisting ~~award~~taxable temporary differences, (ii) future taxable income exclusive of ~~equity~~reversing ~~instruments~~temporary ~~based~~differences onand ~~the~~carry-forwards, (iii) ~~grant~~future ~~date~~taxable ~~fair~~income ~~value~~arising from implementing tax planning strategies, and (iv) specific known trend of ~~such~~profits ~~instruments~~expected ~~over~~to ~~the~~be reflected ~~vesting~~within ~~period~~the industry.

~~Income Taxes~~7

~~Income~~GENUFOOD ~~taxes~~ENERGY ~~are accounted for under the asset~~ENZYMES ~~and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between~~CORP ~~the~~NOTES ~~financial~~TO ~~statement~~CONDENSED ~~carrying~~CONSOLIDATED ~~amounts~~FINANCIAL of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized.STATEMENTS

The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (iUNAUDITED) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.

The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.

There were no current and deferred income tax provision recorded for the ~~nine~~three months ended ~~June~~December 3031, 2022 and 2021 since the Company is in developing stage and did not generate any revenues in the two fiscal periods.

8Recent Accounting Pronouncements

~~Recent~~The Company considers the applicability and impact of all Accounting ~~Pronouncements~~Standards Updates (“ASUs” or “ASU”) on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that the Company feels may be applicable to the Company are as follows:

~~The~~In ~~Company~~August ~~considers~~2020, the ~~applicability~~FASB ~~and~~issued ~~impact~~Accounting ofStandards ~~all~~Update ~~Accounting~~No. ~~Standards~~2020-06, ~~Updates~~Debt ~~(“ASUs”~~– orDebt ~~“ASU”~~with Conversion and Other Options (Subtopic 470-20) onand Derivatives ~~the~~and ~~Company~~Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments ~~consolidated~~and Contracts in an Entity’s Own Equity. This ASU addresses complex financial ~~statements~~instruments that have characteristics of both debt and equity. ~~Updates~~The ~~not~~application ~~listed~~of ~~below~~this ~~were~~ASU ~~assessed~~would reduce the number of accounting models for convertible debt instruments and ~~determined~~convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be ~~either~~subject ~~not~~to ~~applicable~~separation ormodels are ~~expected~~(1) tothose with ~~have~~embedded ~~minimal~~conversion ~~impact~~features onthat are not clearly and closely related to the ~~Company’s~~host ~~consolidated~~contract, ~~financial~~that ~~position~~meet orthe ~~results~~definition of ~~operations.~~a ~~Recently~~derivative, and ~~issued~~that ~~ASUs~~do ~~that~~not ~~the~~qualify ~~Company feels~~for ~~may~~a bescope ~~applicable~~exception tofrom derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the ~~Company~~premiums are recorded as ~~follows:~~paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.

~~In August~~NOTE ~~2020,~~3 ~~the FASB issued Accounting Standards Update No. 2020-06, Debt~~ – ~~Debt~~GOING with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This ASU addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. To date, no such bifurcation has been necessary. Management is evaluating the potential impact. This ASU becomes effective for fiscal years beginning after December 15, 2023.CONCERN

InAs March 2020, the FASB issued Accounting Standards Update No. 2020-03, Codification Improvements to Financial Instruments. There are seven issues addressed in this update. Issues 1 through 5 were clarifications and codifications of ~~previous updates. Issue 3 relates only to depository~~December ~~and~~31, ~~lending~~2022 ~~institutions~~ and ~~therefore~~September ~~would~~30, ~~not~~2022, ~~be applicable to~~ the Company. ~~Issue~~had 6an ~~was~~accumulated adeficit ~~clarification on determining the contractual term~~ of a$10,128,993 and ~~net~~$9,922,955, ~~investment~~respectively. inTo ~~a lease for purposes of measuring expected credit losses~~date, ~~an issue not applicable to~~ the Company.’s ~~Issue~~cash ~~7 relates~~flow torequirements ~~the~~have ~~regaining~~been ~~control~~primarily ofmet ~~financial~~through ~~assets~~proceeds ~~sold~~received ~~and~~from ~~the~~sales ~~recordation~~ of anCommon ~~allowance~~Stock ~~for~~and ~~credit losses~~investment. ~~The amendment related~~These ~~to issues 1, 2, 4~~ and 5other ~~become~~factors ~~effective~~raise ~~immediately~~substantial ~~upon~~doubt ~~adoption~~about of the ~~update.~~Company’s ~~Issue~~ability 3to ~~becomes~~continue ~~effective~~as ~~for~~a ~~fiscal~~going ~~years~~concern. ~~beginning after~~These ~~December~~consolidated ~~15,~~financial statements ~~2019.~~do ~~Issues~~not 6include ~~and~~any 7adjustments ~~become~~to ~~effective~~reflect onthe ~~varying~~possible ~~dates~~future ~~that~~effects ~~relate~~on to the ~~dates~~recoverability ofand ~~adoption~~classification ~~other~~of ~~updates.~~assets ~~Management’s~~and ~~initial~~liabilities ~~analysis is~~ that itmay ~~does~~result ~~not~~in ~~believe~~ the ~~new~~Company ~~guidance~~not ~~will~~being ~~substantially~~able ~~impact~~to ~~the~~continue ~~Company’s~~as ~~financial~~a ~~statements~~going concern.

~~NOTE~~The 3Company –sold ~~GOING~~the 140,000 Hukui Shares ~~CONCERN~~for $350,000 cash on November 19, 2021. The proceeds have been used for operation expenses. Management is currently seeking additional funds for the Company’s future operation.

As of June 30, 2022 and September 30, 2021, the Company had an accumulated deficit of $9,755,968 and $9,522,821, respectively. To date, the Company’s cash flow requirements have been primarily met through proceeds received from sales of Common Stock. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.8

~~The~~GENUFOOD ~~Company sold~~ENERGY ~~the 140,000 Hukui Shares for $350,000 cash on November 19, 2021. The proceeds will be used for operation expenses. Management believes~~ENZYMES ~~that~~CORP NOTES ~~these~~TO ~~funds~~CONDENSED ~~are~~CONSOLIDATED ~~sufficient~~FINANCIAL ~~to fund the Company’s expenses for at least the next 12 months.~~STATEMENTS

~~NOTE 4 – INVESTMENT~~(UNAUDITED)

~~Pursuant to~~NOTE ~~that~~4 ~~certain~~– ~~Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (the “Hukui~~EQUIPMENT Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s total equity with no significant control over or influence on Hukui. The investment is recorded at cost.

9As of December 31, 2022 and September 30, 2022, the Company had equipment of $15,005 and $0, respectively, consisting of equipment to be installed at its electric vehicle charging stations.

~~On November~~NOTE ~~17,~~5 ~~2021,~~– the Company entered into a stock purchase agreement to sell all 140,000 Hukui Shares at $2.50 per share for a total of $350,000. The sale was completed on November 19, 2021, resulting in loss of $1,050,000. The Company recognized impairment loss of the market value of the shares of $1,050,000 for the year ended September 30, 2021.INVESTMENT

~~NOTE~~Pursuant to 5that –certain ~~STOCKHOLDERS~~Series C Preferred Shares Subscription Agreement dated September 23, 2020 between the Company and Hukui (the “Hukui Agreement”), the Company agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $800,000; and on June 25, 2021, the Company purchased an additional 60,000 shares of Series C Preferred Stock at $10.00 per share, for a total purchase price of $600,000. The total $1,400,000 investment consists of less than 20% of Hukui’s ~~EQUITY~~total equity with no significant control over or influence on Hukui. The investment is recorded at cost.

~~The~~On ~~Company~~November 17, is2021, ~~authorized~~the ~~under~~Company ~~its~~entered ~~articles~~into ~~of incorporation,~~a asstock ~~amended,~~purchase agreement to ~~issue~~sell 10all 140,000 Hukui Shares at $2.50 per share for a total of $350,000. The sale was completed on November 19,~~000~~ ~~shares~~2021, ofresulting ~~Common~~in ~~Stock~~loss of $1,050,000. ~~par~~The Company recognized impairment loss of the market value of the shares of $~~0.001~~1,050,000 for ~~per~~the ~~share~~year ended September 30, 2021.

~~Issuance~~NOTE 6 of– ~~Common~~STOCKHOLDERS’ ~~Stock~~EQUITY (DEFICIT)

OnThe ~~December 15, 2020, the~~ Company ~~completed a~~ ~~private~~is ~~offering~~authorized ofunder its ~~Common~~articles ~~Stock.~~of ~~The~~incorporation, ~~Company~~as ~~sold~~amended, ~~107~~to issue 10,000,000 ,000 shares of ~~its~~ Common Stock, topar 34value ~~individuals at a purchase price of~~ $0.01 001 per ~~share, for gross proceeds of $1,070,000, before allocating certain expenses associated with the offering in the amount of $5,852~~ ~~as adjusted paid-in capital~~share.

~~Effective March 31, 2021, the Company issued an aggregate 6,399,965 shares of its Common~~ Stock ~~to certain of its directors, officers, employees and a consultant, who converted accrued~~ and unpaid compensation in the aggregate amount of $94,398. Of this amount, (i) $37,998 was with respect to amounts accrued during fiscal year 2020 and was converted at a rate of $0.05 per share into an aggregate 759,965 shares of its Common Stock; and (ii) $56,400 was with respect to amount accrued during the six months ended March 31, 2021 and was converted at a rate of $0.01 per share into an aggregate 5,640,000 shares of its Common Stock.Options

~~During~~On ~~the year ended September 30~~July 15, ~~2021~~2022, ~~one of~~ the ~~Company’s~~CEO, ~~shareholders~~David ~~made~~Tang, awas ~~loan~~granted 15,000,000 options to ~~the~~purchase ~~Company~~shares inat ~~the~~$0.01 per ~~principal~~share. ~~amount~~As of ~~$30~~December 31,~~000~~ 2022, ~~primarily~~total tooptions ~~pay~~granted ~~our~~was 15,000,000 and ~~expenses~~none was vested. ~~The loan~~This ~~bore~~option ~~simple~~will ~~interest~~be atsubject to a ~~rate~~vesting ofschedule 4providing for twenty-five percent (25%) ~~per~~vesting ~~annum~~after ~~and~~the ~~was~~first ~~payable~~twelve as(12) tomonths ~~both~~of ~~principal~~employment and ~~interest~~monthly onvesting as to the ~~maturity~~remaining ~~date~~seventy-five percent (75%) of ~~April~~the ~~9, 2021.~~shares Onover the ~~maturity~~following ~~date,~~thirty-six (36) months after the ~~holder~~first anniversary of the ~~note~~employment ~~converted~~commencement ~~the~~date. These ~~outstanding~~stock ~~principal,~~options ~~together~~are ~~with~~exercisable ~~accrued~~over ~~and~~a ~~unpaid~~maximum ~~interest~~period of 10 years ~~$598, into~~from ~~3,059,836~~the ~~shares~~grant ofdate. ~~the~~The ~~Company’s~~weighted ~~Common~~average ~~Stock,~~grant atdate fair value of options granted during the ~~rate~~year ofended September 30, 2022 was $0.~~01 per share~~02.

OnCompensation costs ~~June~~associated ~~15,~~with ~~2021,~~ the Company’s ~~sold~~stock ~~and~~options ~~issued 63~~are recognized,~~000,000~~ ~~shares~~based ofon ~~Common~~the ~~Stock~~grant-date tofair 18value ~~individuals, at purchase price~~ of ~~$0.01~~these ~~per share~~options, ~~from~~over athe requisite ~~private~~service ~~offering~~period, ofor ~~its~~vesting ~~Common~~period. ~~Stock (~~Accordingly, the ~~“Spring~~Company ~~2021~~recognized ~~Offering”).~~stock-based ~~The~~compensation ~~gross~~expense ~~proceeds~~of ~~were~~ $~~630~~75,000 and $0, ~~before~~respectively, ~~allocating~~which ~~certain~~was ~~expenses~~included ~~associated~~in ~~with~~ the ~~offering~~ general and administrative expenses in the ~~amount~~condensed consolidated statements of ~~$7,230~~operations for asthe ~~adjusted~~three ~~paid-in~~months ~~capital~~ended December 31, 2022 and 2021.

On July 15, 2021, the Company completed the Spring 2021 Offering of its Common Stock, on which date it sold and issued additional 10,000,000 shares of its Common Stock to five individuals at a purchase price of $0.01 per share, for gross proceeds of $100,000, before allocating certain expenses associated with the offering in the amount of $959 as adjusted paid-in capital.9

~~Effective September~~GENUFOOD ~~30,~~ENERGY ~~2021, the Company issued an aggregate 6,144,000 shares of its Common Stock to certain of its directors, officers, employees~~ENZYMES ~~and~~CORP NOTES aTO ~~consultant,~~CONDENSED ~~who~~CONSOLIDATED ~~converted~~FINANCIAL ~~accrued and unpaid compensation in the aggregate amount of $61,440.~~STATEMENTS

10(UNAUDITED)

~~NOTE~~The 6fair value –of ~~RELATED~~the ~~PARTY~~stock ~~TRANSACTIONS~~options listed above was determined using the Black-Scholes option pricing model with the following assumptions:

Related Parties

	September 30, 2022			September 30, 2021
Risk-free interest rate		2.99	%		–
Expected term		6.08 years			–
Expected volatility		379.35	%		–
Expected dividend yield		0	%		–

~~Name~~The offollowing is ~~related~~a ~~parties~~summary ~~Relationship~~of ~~with~~ the ~~Company~~option Yiactivity ~~Lung~~for ~~(Oliver)~~the ~~Lin~~three ~~Principal~~months ~~shareholder~~ended ~~Jui~~December ~~Pin (John) Lin Principal shareholder~~31, Director, Former President and Chief Executive Officer Jia Tian (Jeffery) Lin Former Chief Executive Officer Wen-Piao (Jack) Lai Director, Former Chief Executive Officer Shao-Cheng (Will) Wang Chief Financial Officer Kuang Ming (James) Tsai Director Nan-Yao (Jake) Chan Former Director Hsin-Ta (Darren) Su Director, Treasurer2022:

Due to Related Parties

Options	Number of Underlying Shares		Weighted average exercise price		Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
Outstanding at October 1, 2022		15,000,000	$	0.01		–	$	–
Granted		–	$	–		–	$	–
Exercised		–	$	–		–	$	–
Forfeited or expired		–	$	–		–	$	–
Outstanding at December 31, 2022		15,000,000	$	0.01		9.5	$	330,000
Vested and expected to vest as of December 31, 2022		15,000,000	$	0.01		9.5	$	330,000
Exercisable at December 31, 2022		–	$	–		–	$	–

~~The~~As ~~Company’s~~of December ~~due~~31, 2022, unrecognized total compensation cost associated with these options was $161,712. This expense is expected to ~~related~~be recognized ~~parties~~over ~~balances~~a ~~are~~weighted-average asperiod ~~follows:~~of 3.54 years.

	June 30, 2022		September 30, 2021
Kuang Ming (James) Tsai	$	15,500	$	1,000
Jui Pin (John) Lin		7,619		1,510
Jia Tian (Jeffery) Lin		2,500		-
Shao-Cheng (Will) Wang		20,700		-
Wen-Piao (Jack) Lai		21,000		-
Hsin-Ta (Darren) Su		19,679		500
Total	$	86,998	$	3,010

NOTE 7 – RELATED PARTY TRANSACTIONS

~~The~~Related ~~related party balances are unsecured, interest-free and due on demand.~~Parties

~~NOTE~~Name 7of –related ~~INCOME~~parties ~~TAXES~~Relationship with the Company Yi Lung (Oliver) Lin Principal shareholder Jui Pin (John) Lin Principal shareholder, Director, Former President and Chief Executive Officer Jia Tian (Jeffery) Lin Former Chief Executive Officer Wen-Piao (Jack) Lai Director, Former President and Chief Executive Officer Shao-Cheng (Will) Wang Chief Financial Officer Kuang Ming (James) Tsai Director Nan-Yao (Jake) Chan Former Director Hsin-Ta (Darren) Su Director, Treasurer Hui-Chuan (Sandra) Lin Director and Secretary, daughter of Jui Pin (John) Lin

The Company has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even though the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively, and the Singapore subsidiary has been inactive since 2016.10

~~During~~GENUFOOD ~~the fiscal~~ENERGY ~~year ended September 30, 2021, the IRS imposed a $25,000 penalty on the Company for failure to file Form 5472, Information Return~~ENZYMES ~~of a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30,~~CORP ~~2020.~~NOTES ~~The~~TO ~~Company~~CONDENSED ~~has~~CONSOLIDATED ~~engaged~~FINANCIAL ~~an outside professional advisor to seek for forgiveness of the penalty and interest thereon in the amount of $3,476, for a total of $28,476, which was still pending as of June 30, 2022.~~STATEMENTS

~~NOTE 8 – COMMITMENTS AND CONTINGENCIES~~(UNAUDITED)

~~The Company terminated its previous virtual office~~Due ~~agreement in Los Angeles, California and has established a new virtual office in Arcadia, California. The new arrangement is on a month-~~to~~-month basis~~ atRelated ~~a cost of $200 per month. As of June 30, 2022, the Company had no material commitments under operating leases.~~Parties

~~During~~The ~~the fiscal year ended September 30, 2021,~~Company’s ~~the~~due ~~IRS imposed a $25,000 penalty on the Company for failure~~ to ~~file~~related ~~Form~~parties ~~5472,~~balances ~~Information~~are ~~Return of~~as ~~a 25% Foreign-Owned U.S. Corporation or a Foreign Corporation Engaged in a U.S. Trade or Business, for the year ended September 30, 2020 (see Note 7).~~follows:

NOTE 9 – SUBSEQUENT EVENTS

	December 31, 2022		September 30, 2022
Kuang Ming (James) Tsai	$	26,155	$	20,755
Jui Pin (John) Lin		17,048		8,048
Jia Tian (Jeffery) Lin		2,500		2,500
Shao-Cheng (Will) Wang		34,500		27,600
Wen-Piao (Jack) Lai		24,010		22,210
Hsin-Ta (Darren) Su		18,271		17,189
Hui-Chuan (Sandra) Lin		9,929		4,529
Nao-Yao (Jake) Chan		1,800		-
Total	$	134,213	$	102,831

~~Management~~The ~~has evaluated subsequent events pursuant~~related toparty ~~the~~balances ~~requirements~~are ~~of ASC Topic 855~~unsecured, ~~from~~interest-free ~~the balance sheet date through the date when the condensed consolidated financial statements were issued,~~ and ~~determined~~due ~~that~~on ~~no subsequent events occurred that would require adjustment to or disclosure in the condensed consolidated financial statements~~demand.

11NOTE 8 – INCOME TAXES

~~ITEM~~The 2Company has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. ~~MANAGEMENT’~~Management believes GEEC does not have any U.S. ~~DISCUSSION~~income ~~AND~~tax ~~ANALYSIS~~liability OFdue. ~~FINANCIAL~~However, ~~CONDITION~~even ~~AND~~though ~~RESULTS~~the OFCompany ~~OPERATIONS~~does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively, and the Singapore subsidiary has been inactive since 2016.

~~CAUTIONARY~~Internal Revenue ~~STATEMENT~~Code ~~REGARDING~~(“IRC”) ~~FORWARD-LOOKING~~Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471) ~~STATEMENTS~~and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10,000 for each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate information described in Section 6038(a). According to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.

~~This~~The ~~document contains “forward-looking~~Company ~~statements”~~believes ~~within~~that ~~the~~based ~~meaning~~on of the ~~Private~~current ~~Securities~~information ~~Litigation Reform Act of 1995~~available, ~~Section 27A~~it ofis ~~the~~difficult ~~Securities~~to ~~Act~~determine ~~of 1933~~whether ~~and~~it ~~Section 21E~~is ofprobable that the ~~Securities~~Company ~~Exchange~~will ~~Act~~be charged ofpenalties ~~1934.~~by ~~All~~IRS ~~statements~~for ~~other~~the ~~than~~late ~~statements~~filing of ~~historical~~Form ~~fact~~5471 ~~are~~and ~~“forward-looking statements”~~even ~~for~~if ~~purposes~~it ofwill ~~federal and state securities laws~~be, ~~including,~~it ~~but~~is ~~not~~difficult ~~limited~~ to, ~~any~~reasonably ~~projections~~estimate ~~of earnings, revenue or other financial items; any statements of~~ the ~~plans,~~amount ~~strategies and objectives~~ of ~~management for future operations; any statements concerning~~ ~~proposed~~penalties ~~new~~that ~~services~~may orbe ~~developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing~~assessed.

~~Forward-looking~~During ~~statements~~the ~~may~~fiscal ~~include~~year ~~the~~ended ~~words~~September ~~“may~~30,” ~~“could~~2021,” ~~“will,”~~the ~~“estimate,”~~IRS ~~“intend,”~~imposed ~~“continue,” “believe,”~~a ~~“expect”~~$25,000 penalty ~~“anticipate”~~on the Company for failure to file Form 5472, ~~“hope”~~Information Return orof ~~other~~a 25% ~~similar~~Foreign-Owned ~~words~~U.S. ~~These~~Corporation ~~forward-looking statements~~or ~~present~~a ~~our~~Foreign ~~estimates~~Corporation ~~and~~Engaged ~~assumptions~~in ~~only~~a asU.S. ofTrade or Business, for the ~~date~~year ofended ~~this~~September 30, ~~report~~2020. ~~Except~~The ~~for~~Company ~~our~~has ~~ongoing~~engaged ~~obligation~~an tooutside ~~disclose~~professional ~~material information~~advisor asto ~~required~~seek byfor forgiveness of the ~~federal~~penalty ~~securities~~and ~~laws,~~interest wethereon doin ~~not~~the ~~intend~~amount of $4,976, ~~and~~for ~~undertake~~a nototal ~~obligation~~of $29,976, towhich ~~update~~was ~~any~~still ~~forward-looking~~pending ~~statement~~as of December 31, 2022.

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. Some of the key factors impacting these risks and uncertainties include, but are not limited to:11

●GENUFOOD ~~risks~~ENERGY ~~related~~ENZYMES CORP NOTES toTO ~~our~~CONDENSED ~~ability~~CONSOLIDATED toFINANCIAL ~~identify, pursue and commence a reverse merger and/or a possible operating business;~~STATEMENTS

~~● our ability to obtain adequate funding to complete a reverse merger or commence a possible operating business and meet our operating expenses on a current basis;~~(UNAUDITED)

●NOTE 9 ~~general~~– ~~economic~~COMMITMENTS ~~uncertainty,~~AND ~~whether as a result of the COVID-19 pandemic or otherwise;~~CONTINGENCIES

●The ~~delays~~Company terminated inits ~~our~~previous ~~ability~~virtual tooffice ~~obtain~~agreement ~~any~~in ~~necessary~~Los ~~business~~Angeles, ~~licenses~~California and ~~permits,~~has ~~and~~established ~~commence~~a ~~business~~new ~~operations~~virtual office in Arcadia, ~~whether~~California. The asnew arrangement is on a ~~result~~month-to-month basis at a cost of $200 per month. As of December 31, 2022, the ~~COVID-19~~Company ~~pandemic~~had orno ~~otherwise;~~material commitments ~~and~~under operating leases.

●During ~~current~~the fiscal ~~and~~year ~~longer-term~~ended ~~economic~~September ~~and~~30, ~~other~~2021, ~~impacts~~the ofIRS ~~the~~imposed ~~COVID-19~~a ~~pandemic~~$25,000 penalty on ~~our~~the ~~operations,~~Company ~~results~~for offailure ~~operations~~to ~~and~~file ~~financial~~Form ~~condition~~5472, ~~including~~Information Return ~~without~~of ~~limitation~~a 25% ~~changes in consumer spending patterns for non~~Foreign-~~essential~~Owned ~~products,~~U.S. ~~resulting~~Corporation ~~from~~or ~~the~~a ~~economic~~Foreign ~~crisis~~Corporation ~~caused~~Engaged byin ~~lockdown,~~a ~~shelter-in-place,~~U.S. ~~stay-at-home~~Trade or ~~similar~~Business, ~~orders~~for ~~instituted~~the asyear aended ~~result~~September 30, of2020 ~~the~~(see ~~pandemic,~~Note ~~or otherwise~~8).

~~Overview~~NOTE 10 – SUBSEQUENT EVENTS

WeThe ~~currently have no operations.~~Company ~~However,~~has onclosed ~~August 1~~GESPL, ~~2022, the Board of the Company approved to expand the Company’s business in the area of electric vehicle supply equipment and will direct the management team to implement~~ its ~~new~~Singapore ~~business plan in such industry. We will continue to need capital to meet our expenses~~subsidiary, ~~primarily~~as ~~overhead and the professional fees related to the cost~~ of ~~compliance~~January as9, ~~a reporting company~~2023. ToGESPL dodoes ~~so,~~not ~~we may~~have ~~raise equity, debt, convertible debt or a combination of~~ any ~~of the foregoing~~operation. ~~However, there are no commitments in place to fund our capital requirements and no guarantee can be given that we will be able to secure such funding on terms that are favorable to us, or at all.~~

12Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855, from the balance sheet date through the date when the consolidated financial statements were issued and determined that no subsequent events occurred that would require adjustment to or disclosure in the consolidated financial statements.

~~Hukui Investment~~12

~~Hukui Biotechnology Corporation~~ITEM 2. (“Hukui”) and we entered into a Series C Preferred Shares Subscription Agreement dated September 23, 2020 (the “Hukui Agreement”), pursuant to which we agreed to purchase an aggregate 200,000 shares of HukuiMANAGEMENT’sS ~~Series~~DISCUSSION CAND ~~Preferred~~ANALYSIS ~~Stock~~OF ~~(the “Series~~FINANCIAL CCONDITION ~~Preferred~~AND ~~Shares”)~~RESULTS atOF ~~$10~~OPERATIONS.~~00 per share, for an aggregate investment of $2,000,000.~~

~~The Hukui Agreement provided~~CAUTIONARY ~~that~~STATEMENT weREGARDING ~~would~~FORWARD-LOOKING ~~purchase the Series C Preferred Shares in three tranches, through a date on or before June 30, 2022, as follows:~~STATEMENTS

●This document ~~The~~contains ~~first~~“forward-looking ~~tranche~~statements” iswithin ~~80,000~~the ~~Series~~meaning Cof ~~Preferred~~the ~~Shares~~Private inSecurities ~~the~~Litigation ~~amount~~Reform Act of ~~$800~~1995,~~000~~ Section 27A (of the ~~“First~~Securities ~~Tranche~~Act ~~Investment~~of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements”), ~~such~~for ~~shares~~purposes ~~having~~of ~~been~~federal ~~purchased~~and bystate ussecurities onlaws, ~~December~~including, but 15not limited to, ~~2020~~any (projections of earnings, revenue or other financial items; any statements of the ~~“First~~plans, ~~Tranche~~strategies ~~Closing”)~~and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

●Forward-looking statements ~~The~~may ~~second~~include ~~tranche~~the iswords 60“may,~~000~~” ~~Series~~“could,” C“will,” ~~Preferred~~“estimate,” ~~Shares~~“intend,” “continue,” in“believe,” “expect”, “anticipate”, “hope” or other similar words. These forward-looking statements present our estimates and assumptions only as of the ~~amount~~date of ~~$600,000~~this ~~(the~~report. ~~“Second~~Except ~~Tranche~~for ~~Investment”),~~our ~~such~~ongoing ~~shares~~obligation to ~~having~~disclose ~~been~~material ~~purchased~~information as required by usthe onfederal ~~June~~securities 25laws, ~~2021~~we ~~(the~~do ~~“Second~~not ~~Tranche~~intend, ~~Closing”);~~ and undertake no obligation, to update any forward-looking statement.

●Although we ~~The~~believe ~~third~~that ~~tranche~~the isexpectations 60reflected in any of our forward-looking statements are reasonable,~~000~~ ~~Series~~actual Cresults ~~Preferred~~could ~~Shares~~differ materially from those projected or assumed in ~~the~~any ~~amount~~of our forward-looking statements. Our future financial condition and results of ~~$600~~operations,~~000~~ ~~(the~~as well ~~“Third~~as ~~Tranche~~any ~~Investment”)~~forward-looking statements, ~~such~~are ~~shares~~subject to ~~have~~change ~~been~~and ~~purchased~~inherent onrisks orand ~~before~~uncertainties. ~~June~~Some 30of the key factors impacting these risks and uncertainties include, ~~2022~~but ~~(the~~are ~~“Third~~not ~~Tranche~~limited ~~Closing”).~~to:

An● ~~individual~~risks ~~and~~related ~~resident of the Republic of China (the “Purchaser”), Hukui and we entered into a Stock Purchase Agreement dated as of November 17, 2021 (the “Stock Purchase Agreement”), pursuant~~ to ~~which~~our weability ~~agreed~~ to ~~sell the 140~~identify,~~000~~ ~~shares~~pursue ~~of Hukui’s Series C Preferred Stock that we had purchased in the First Tranche Closing~~ and ~~the~~commence ~~Second~~a ~~Tranche~~reverse ~~Closing~~merger ~~(the “Hukui Shares”) to the Purchaser for $350,000 in cash,~~ and/or ~~$2.50~~a ~~per~~possible ~~share.~~operating ~~The sale of the Hukui Shares closed on November 19, 2021.~~business;

On● ~~December~~our ~~17,~~ability ~~2021,~~to ~~Hukui~~obtain ~~and~~adequate wefunding ~~entered into an Agreement (the “Termination Agreement”), pursuant~~ to ~~which~~complete ~~our~~a ~~obligation~~reverse tomerger ~~make~~or ~~the~~commence ~~Third~~a ~~Tranche~~possible ~~Investment~~operating ~~was~~business ~~terminated~~ and ~~the~~meet ~~Hukui~~our ~~Agreement~~operating ~~was~~expenses ~~terminated.~~on As a ~~result,~~current ~~we have no continuing contractual obligation to make any investment in Hukui.~~basis;

13● general economic uncertainty, whether as a result of the COVID-19 pandemic or otherwise;

~~Results~~● delays in our ability to obtain any necessary business licenses and permits, and commence business operations, whether as a result of ~~Operations~~the COVID-19 pandemic or otherwise; and

~~Three~~● current and longer-~~Month~~term ~~Periods~~economic ~~Ended~~and ~~June~~other 30impacts of the COVID-19 pandemic on our operations, ~~2022 compared~~results toof operations and financial condition, including without limitation changes in consumer spending patterns for non-essential products, resulting from the ~~Three~~economic crisis caused by lockdown, shelter-~~Month~~in-place, ~~Periods~~stay-at-home ~~Ended~~or ~~June~~similar 30orders instituted as a result of the pandemic, ~~2021~~or otherwise.

~~Revenues~~Overview

WeOn ~~did~~August ~~not~~1, ~~generate~~2022, ~~any~~the ~~revenues~~board of directors (the “Board”) ~~during~~of the ~~three-month~~Company ~~periods~~unanimously ~~ended~~approved ~~June~~to 30expand our business in the area of electric vehicle supply equipment (“EVSE”) and will direct the management team to implement its new business plan in such industry. On August 16, 2022, the Company formally announced its intention to reposition as EVSE solutions provider, seeking to grow business in EVSE industry, including building, owning, and ~~2021~~operating the next generation of electric vehicle charging stations in the U.S. The Company intends to bring convenient, reliable, and accessible charging experience to electric vehicle drivers, utilizing frictionless technology and carbon-neutral vehicle-charging infrastructure.

~~Operating~~On October ~~Expenses~~26, 2022, we entered into three Charging Station Site Host Agreements (the “Agreements”) with two institutions (the “Site Hosts”), respectively, pursuant to which the Site Hosts agree to allow us to install our electric vehicle charging stations at the locations set forth in the Agreements (the “Charging Stations”). Under the Agreements, we have agreed to share our revenue generated by the sales of electricity at the Charging Stations with the Site Hosts in accordance with the schedules set forth therein.

WeAs ~~incurred total operating expenses~~ of ~~$65,091~~December ~~and $98~~31,~~941~~ ~~for the three-month periods ended June 30,~~ 2022 ~~and 2021~~, ~~respectively. Our operating expenses consist~~the ofCompany ~~accounting~~has ~~and~~purchased ~~legal~~certain ~~fees,~~electric ~~other~~vehicle ~~professional~~charging ~~fees,~~equipment. ~~payroll expenses~~Furthermore, ~~rent,~~the ~~bank~~Company ~~charges,~~is ~~and~~in ~~transfer~~the ~~agent~~process ~~fees.~~of ~~The~~obtaining ~~decrease~~permits into ~~operating~~construct ~~expenses~~the ~~for~~Charging Stations at the three~~-month~~ ~~periods~~confirmed ~~ended~~sites. ~~June~~As 30of December 31, 2022, ~~compared to~~ the ~~same~~Company ~~periods~~contracted ~~ended~~an inarchitectural ~~2021~~firm ~~was~~on providing ~~primarily~~designing ~~due~~and toengineering ~~decrease in~~services ~~legal~~for ~~fees~~two sites, and ~~other~~working ~~professional~~on ~~fees~~technical ~~related~~issues tofor the ~~fundraising,~~third ~~investment, and filings~~site.

~~Other~~As ~~expense~~of February 13, 2023, the Company has received the finalized site plans and electrical diagrams from the architectural firm and electrical engineers for 2 sites. The Company has also received permission from the site owners to proceed with the charging station construction permit applications with the local municipalities. The Company expects to install up to a total of 10 charging units for the first 2 sites, and have them operational in April of 2023.

During the three-month periods ended June 30, 2022, we incurred $745 other expenses mainly due to interest incurred for unpaid penalty from IRS. During the three-month periods ended June 30, 2021, we incurred $64,896 other income mainly due to debt forgiveness and offsets with interest incurred for amounts borrowed to fund operating expenses.13

~~Net Loss~~Hukui Investment

AsHukui Biotechnology aCorporation ~~result~~(“Hukui”) ofand ~~the~~we ~~above,~~entered ~~our net~~into ~~loss~~a ~~increased~~Series ~~from~~C ~~$34~~Preferred Shares Subscription Agreement dated September 23,~~045~~ in2020 (the ~~three-month~~“Hukui ~~periods~~Agreement”), ~~ended~~pursuant ~~June~~to ~~30,~~which ~~2021~~we agreed to ~~$65~~purchase an aggregate 200,~~836~~000 inshares of Hukui’s Series C Preferred Stock (the ~~same~~“Series ~~periods~~C ~~ended~~Preferred inShares”) ~~2022~~at $10.00 per share, for an aggregate investment of $2,000,000.

~~Nine-Month~~The Hukui ~~Periods~~Agreement ~~Ended~~provided ~~June~~that ~~30,~~we ~~2022 compared~~would topurchase the ~~Nine-Month~~Series ~~Periods~~C ~~Ended~~Preferred Shares in three tranches, through a date on or before June 30, 2022, ~~2021~~as follows:

~~Revenues~~● The first tranche is 80,000 Series C Preferred Shares in the amount of $800,000 (the “First Tranche Investment”), such shares having been purchased by us on December 15, 2020 (the “First Tranche Closing”);

We● ~~did~~The ~~not~~second ~~generate~~tranche ~~any~~is ~~revenues during~~60,000 Series C Preferred Shares in the ~~nine-month~~amount ~~periods~~of ~~ended~~$600,000 ~~June~~(the 30“Second Tranche Investment”), ~~2022~~such ~~and~~shares having been purchased by us on June 25, 2021. (the “Second Tranche Closing”); and

~~Operating~~● ~~Expenses~~The third tranche is 60,000 Series C Preferred Shares in the amount of $600,000 (the “Third Tranche Investment”), such shares to have been purchased on or before June 30, 2022 (the “Third Tranche Closing”).

WeAn individual ~~incurred~~and ~~total~~resident ~~operating expenses~~of the Republic of ~~$230~~China (the “Purchaser”),~~516~~ Hukui and ~~$262,516~~we ~~for~~entered ~~the~~into ~~nine-month~~a ~~periods~~Stock ~~ended~~Purchase ~~June~~Agreement dated ~~30,~~as ~~2022~~of ~~and~~November ~~2021~~17, ~~respectively.~~2021 ~~Our~~(the ~~operating~~“Stock ~~expenses~~Purchase ~~consist of~~Agreement”), ~~accounting~~pursuant ~~and~~to ~~legal~~which ~~fees,~~we ~~other~~agreed ~~professional~~to ~~fees,~~sell ~~payroll~~the ~~expenses~~140,000 ~~rent,~~shares ~~bank~~of Hukui’s ~~charges,~~Series ~~and~~C ~~transfer~~Preferred ~~agent~~Stock ~~fees.~~that ~~The~~we ~~decrease~~had purchased in ~~operating~~ ~~expenses~~the ~~for~~First ~~the~~Tranche ~~nine-month~~Closing ~~periods~~and ~~ended~~the ~~June~~Second ~~30,~~Tranche ~~2022~~Closing ~~compared~~(the “Hukui Shares”) to the ~~same~~Purchaser ~~periods~~for ~~ended~~$350,000 in ~~2021~~cash, ~~was~~or ~~primarily~~$2.50 ~~due~~per toshare. ~~decrease in~~The ~~legal~~sale ~~fees~~of ~~and~~the ~~other~~Hukui ~~professional~~Shares ~~fees~~closed ~~related~~on toNovember ~~filings~~19, 2021.

~~Other~~On December ~~expense~~17, 2021, Hukui and we entered into an Agreement (the “Termination Agreement”), pursuant to which our obligation to make the Third Tranche Investment was terminated and the Hukui Agreement was terminated. As a result, we have no continuing contractual obligation to make any investment in Hukui.

During the nine-month periods ended June 30, 2022, we incurred $2,631 other expenses mainly due to interest incurred for unpaid penalty from IRS. During the mine-month periods ended June 30, 2021, we incurred $64,343 other income mainly due to debt forgiveness, and offsets with interest incurred for amount borrowed to fund operating expenses.14

~~Net~~Results ~~Loss~~of Operations

AsThree aMonths Ended ~~result~~December ~~of the above~~31, ~~our net~~2022 ~~loss~~compared ~~increased~~to ~~from $198,973 in~~ the ~~nine-month~~Three ~~periods~~Months ~~ended~~Ended ~~June~~December 3031, 2021 ~~to $233,147 in the same periods ended in 2022.~~

14Revenues

~~Effect~~We did ofnot generate any revenues during the ~~COVID-19~~three ~~Pandemic~~months onended ~~our~~December ~~Business~~31, 2022 and 2021.

~~While~~Operating our liquidity and capital resources are severely limited and present serious obstacles to starting a business, these limitations are unrelated to the COVID-19 pandemic and resulting global economic crisis.Expenses

~~Our~~We ~~personnel~~incurred ~~are in Taiwan,~~total ~~which~~operating ~~has~~expenses ~~been~~of ~~relatively~~$205,245 ~~less~~and ~~affected~~$103,340 byfor the ~~pandemic~~three ~~compared~~months toended ~~many~~December ~~other countries in Asia~~31, ~~Europe~~2022 and ~~the~~2021, ~~United States~~respectively. ~~However,~~Our operating ~~even~~expenses ~~before~~consist anof ~~increase~~legal infees, ~~the~~other ~~number~~professional offees, ~~cases~~payroll ofexpenses, ~~COVID~~stock-19based incompensation, ~~Taiwan~~rent, webank ~~experienced~~charges, ~~delays in obtaining business licenses~~ and ~~permits,~~ ~~and~~transfer ~~any~~agent ~~other~~fees. ~~governmental~~The ~~approvals~~increase ~~that~~in ~~might~~operating ~~have~~expenses ~~been required~~ for ~~businesses~~the ~~that~~three wemonths ~~previously~~ended ~~considered~~December ~~commencing~~31, ~~since~~2022 ~~government offices~~compared ~~have~~to ~~been~~the ~~working~~same ~~with~~period ~~reduced~~in 2021 ~~staff~~was ~~during~~primarily ~~the~~due ~~pandemic.~~to Wethe ~~expect~~increase ~~this~~in ~~situation~~payroll toexpenses, ~~continue~~ and ~~possibly~~stock-based ~~become more challenging depending upon the duration of the pandemic~~compensation.

~~Depending~~Other upon the extent and duration of the pandemic and the resulting global economic crisis, these conditions may have an adverse impact on our ability to raise capital and commence any business we may pursue.expense

~~Liquidity~~During the ~~and~~three ~~Capital~~months ~~Resources~~ended December 31, 2022, we incurred $793 other expenses mainly due to interest incurred for unpaid penalty from IRS. During the three months ended December 31, 2021, we incurred $747 other expenses mainly due to interest incurred for unpaid penalty from IRS.

~~Working~~Net ~~Capital~~Loss

	June 30,		September 30,
	2022		2021
Current Assets	$	232,812	$	35,044
Current Liabilities		184,023		105,346
Working Capital (Deficit)	$	48,789	$	(70,302	)

As a result of the above, our net loss increased from $104,087 in the three months ended December 31, 2021 to $206,038 in the same period ended in 2022.

AsEffect of ~~June~~the ~~30,~~COVID-19 ~~2022,~~Pandemic weon ~~had~~our ~~current assets of $232,812 and a working capital of $48,789. In comparison, as of September 30, 2021, we had current assets of $35,044 and a working capital deficit of $70,302.~~Business

AsWhile our ofliquidity ~~June~~and ~~30,~~capital ~~2022,~~resources weare ~~had total~~severely ~~assets~~limited ofand ~~$232,812,~~present ~~compared~~serious ~~with~~obstacles ~~total~~to ~~assets~~starting ofa ~~$385~~business,~~044~~ atthese ~~September~~limitations ~~30,~~are ~~2021. The decrease in total assets was primarily due~~unrelated to the ~~sale~~COVID-19 ofpandemic ~~investment~~ and ~~cash~~resulting ~~spent~~global ineconomic ~~operating expenses after selling the 140,000 Hukui Shares for cash~~crisis.

WeOur personnel ~~had~~are ~~$184~~in Taiwan,~~023~~ inwhich ~~total~~has ~~current liabilities~~been asrelatively ofless ~~June~~affected ~~30,~~by ~~2022,~~the ~~consisting~~pandemic ofcompared ~~$97,025~~to inmany ~~accounts~~other ~~payable~~countries ~~and~~in ~~$86~~Asia,~~998~~ ~~due~~Europe toand the ~~related~~United ~~parties~~States. ~~This~~However, iseven ~~compared~~before toan ~~total current~~increase ~~liabilities~~in ofthe ~~$105,346~~number asof cases of ~~September~~COVID-19 ~~30,~~in ~~2021~~Taiwan, ~~consisting~~we ofexperienced ~~$100,746~~delays in ~~accounts~~obtaining ~~payable,~~business licenses $1and permits,~~590~~ inand ~~accrued~~any ~~expenses,~~other ~~and~~governmental approvals that might have been required for businesses that we previously considered $3commencing,~~010~~ ~~due~~since togovernment ~~related~~offices ~~parties~~have been working with reduced staff during the pandemic. ~~The~~We ~~increase~~expect inthis ~~due~~situation to ~~related~~continue ~~parties~~and possibly ~~was~~become ~~primarily~~more ~~due~~challenging todepending ~~unpaid~~upon ~~compensation~~the toduration ~~officers~~of ~~and~~the ~~directors~~pandemic.

~~We had total stockholders’~~Depending ~~equity~~upon ofthe ~~$20,313~~extent and anduration ~~accumulated deficit~~ of ~~$9,755,968~~the aspandemic ofand ~~June~~the ~~30,~~resulting ~~2022.~~global Ineconomic ~~comparison~~crisis, wethese ~~had~~conditions amay ~~total~~have ~~stockholders’~~an ~~equity of~~adverse ~~$253,472~~impact ~~and~~on our anability ~~accumulated~~to ~~deficit~~raise ofcapital ~~$9,522,821~~and ascommence ofany ~~September~~business ~~30,~~we ~~2021~~may pursue.

OnLiquidity ~~December~~and ~~15, 2020, we completed~~Capital a private offering of our Common Stock. We sold 107,000,000 shares of our Common Stock to 34 individuals at a purchase price of $0.01 per share, for gross proceeds of $1,070,000 before allocating certain expenses associated with the offering in the amount of $5,852 as adjusted paid-in capital.Resources

~~Effective~~Working March 31, 2021, we issued an aggregate 6,399,965 shares of our Common Stock to certain of our directors, officers, employees and independent consultants, who converted accrued and unpaid compensation in the aggregate amount of $94,398. Of this amount, (i) $37,998 was with respect to amounts accrued during fiscal year 2020 and was converted at a rate of $0.05 per share into an aggregate 759,965 shares of our Common Stock; and (ii) $56,400 was with respect to amount accrued during fiscal year 2021 through March 31, 2021 and was converted at a rate of $0.01 per share into an aggregate 5,640,000 shares of our Common Stock.Capital

During the year ended September 30, 2021, one of our shareholders made a loan to us in the principal amount of $30,000 (the “October 2020 Loan”), primarily to pay our expenses. The October 2020 Loan bore simple interest at a rate of 4% per annum and was payable as to both principal and interest on the maturity date of April 9, 2021. On the maturity date, the holder of the note evidencing the October 2020 Loan converted the outstanding principal, together with accrued and unpaid interest of $598, into 3,059,836 shares of our Common Stock, at the rate of $0.01 per share.

	December 31,			September 30,
	2022			2022
Current Assets	$	53,183		$	150,893
Current Liabilities		252,684			205,016
Working Capital Deficit	$	(199,501	)	$	(54,123	)

OnAs of ~~June~~December 1531, ~~2021~~2022, we ~~sold~~had ~~and issued~~current ~~63,000,000~~assets ~~shares~~ of ~~our~~$53,183 ~~Common~~and ~~Stock~~a toworking 18deficit ~~individuals at purchase price~~ of $0199,501.01 ~~per~~In ~~share~~comparison, ~~from~~as inof ~~the~~September ~~Spring~~30, ~~2021~~2022, ~~Offering.~~we ~~Gross~~had ~~proceeds~~current ~~were~~assets of $~~630~~150,~~000,~~893 ~~before~~and ~~allocating~~a ~~certain~~working ~~expenses~~capital ~~associated~~deficit ~~with the offering in the amount~~ of $754,~~230 as adjusted paid-in capital~~123.

OnAs ~~July~~of 15December 31, ~~2021~~2022, we ~~completed~~had ~~the~~total ~~Spring~~assets ~~2021 Offering~~ of ~~its Common Stock~~$68, ~~on which date we sold and issued an additional 10~~188,~~000,000 shares of~~ ~~its~~compared ~~Common~~with ~~Stock~~total toassets ~~five individuals at a purchase price~~ of $~~0.01 per share~~150,893 ~~for~~at ~~gross~~September ~~proceeds of $100~~30,~~000,~~ ~~before~~2022. ~~allocating certain~~The ~~expenses~~decrease ~~associated~~in ~~with~~total assets ~~the~~was ~~offering~~primarily indue ~~the~~to ~~amount~~cash ofspent ~~$959~~in asoperating ~~adjusted paid-in-capital~~expenses.

~~Cash~~We had ~~Flows~~$252,684 in total current liabilities as of December 31, 2022, consisting of $118,471 in accounts payable and $134,213 due to related parties. This is compared to total current liabilities of $205,016 as of September 30, 2022, consisting of $102,185 in accounts payable and $102,831 due to related parties. The increase in due to related parties was primarily due to unpaid compensation to officers and directors.

	Nine months ended June 30, 2022			Nine months ended June 30, 2021
Cash flows used in operating activities	$	(148,085	)	$	(186,405	)
Cash flows provided by (used in) investing activities		350,000			(1,400,000	)
Cash flows provided by financing activities		-			1,596,508
Effect of exchange rate changes on cash		(41	)		48
Net increase in cash during period	$	201,874		$	10,151

We had total stockholders’ deficit of $214,472 and an accumulated deficit of $10,128,993 as of December 31, 2022. In comparison, we had a total stockholders’ deficit of $83,349 and an accumulated deficit of $9,922,955 as of September 30, 2022.

~~During~~Cash the nine-month periods ended June 30, 2022, we used $148,085 of cash in operating activities which was attributable primarily to our net loss of $233,147 offset by change in operating assets and liabilities of $85,062. In comparison, during the nine-month periods ended June 30, 2021, we used $186,405 of cash in operating activities which was attributable to our net loss of $198,973 and the change in operating assets and liabilities of $12,568.Flows

With respect to our investing activities, we received $350,000 in payment for the sale of the 140,000 Hukui Shares during the nine-month periods ended June 30, 2022. During the nine-month ended June 30, 2021, we used $1,400,000 for investment in Hukui.

	Three Months Ended December 31, 2022			Three Months Ended December 31, 2021
Cash flows used in operating activities	$	(74,869	)	$	(71,538	)
Cash flows used in investing activities		(15,005	)		350,000
Cash flows provided by financing activities		-			-
Effect of exchange rate changes on cash		-			-
Net increase (decrease) in cash during period	$	(89,874	)	$	278,462

During the ~~nine-month~~three ~~periods~~ months ended ~~June~~December 3031, 2022, we ~~did~~used ~~not have any financing activity. During the nine-month periods ended June 30~~$74,869 ~~2021,~~of ~~we had total~~ cash ~~inflow of~~in ~~$1,596,508~~operating ~~from financing~~ activities. Wewhich ~~repaid~~was ~~$120,410~~attributable primarily to ~~notes payable – related party, which~~ our ~~former President and Chief~~net ~~Executive~~loss ~~Officer,~~of ~~Jui Pin Lin~~$206,038 ~~previously~~offset ~~loaned~~by ~~us.~~stock-based Wecompensation ~~received~~and ~~$30,000~~change asin aoperating ~~loan~~assets ~~from~~and aliabilities ~~shareholder~~ of ~~the Company~~$131,169. WeIn ~~received $1~~comparison,~~686,918,~~ during ~~net~~the ofthree ~~directly~~months ~~associated~~ended ~~expenses,~~December ~~including legal~~31, ~~transfer agent~~2021, ~~and~~we ~~printing~~used ~~and delivery expenses~~$71,538 ~~from~~of acash ~~private~~in ~~offering~~operating ofactivities ~~our Common Stock,~~ which was ~~completed~~attributable inprimarily ~~December~~to ~~2020.~~our ~~For~~net loss ~~accounting~~of ~~purpose~~$104,087 weoffset ~~recorded~~by ~~the~~change ~~net~~in ~~proceeds~~operating ~~from~~assets ~~the~~and ~~private~~liabilities ~~offering instead~~ of ~~the gross amount of~~ $132,~~070,000~~549.

~~There is substantial doubt~~During ~~that we can continue as an ongoing business for~~ the ~~next~~three ~~twelve~~ months ~~unless~~ended weDecember ~~obtain~~31, ~~additional~~2022, ~~capital to pay our expenses as they become due. We do not anticipate any significant additional revenue until and unless~~ we ~~begin~~used to$15,005 ~~execute~~of oncash ~~our~~in ~~plan~~investing ofactivities ~~operations~~for ~~involving~~ the ~~start~~purchase of ~~our new nasal spray business~~equipment. ~~There~~We isreceived ~~no assurance that we will ever reach that stage. The condensed consolidated financial~~$350,000 ~~statements~~in ~~presented~~payment ~~herein~~for ~~do not include any adjustments relating to~~ the ~~recoverability~~sale ~~and classification~~ of ~~recorded~~the ~~assets~~140,000 orHukui ~~the amounts~~Shares ~~and~~during ~~classification of liabilities that might be necessary in~~ the ~~event~~three ~~that~~months weended ~~cannot~~December ~~continue~~31, ~~as a going concern~~2021.

~~Our ability to continue as~~During ~~a going concern is dependent upon our ability to successfully execute our business plan and generate profitable operations in~~ the ~~future, and,~~three ~~until~~months ~~and~~ended ~~unless~~December ~~we achieve that~~31, to2022 ~~obtain the necessary financing to meet our obligations~~ and ~~repay our liabilities arising from normal business operation as and when they become due. To date~~2021, ~~our~~we ~~capital~~did ~~requirements~~not have ~~primarily~~any ~~been~~financing ~~funded by shareholders through the purchase of our Common Stock in private offerings and short-term borrowings from a former officer and another shareholder~~activity.

16There is substantial doubt that we can continue as an ongoing business for the next twelve months unless we obtain additional capital to pay our expenses as they become due. We do not anticipate any significant additional revenue until we continue to implement our electric vehicle charging station business operations and begin to profit from our business operations. There is no assurance that we will ever reach that stage. The condensed consolidated financial statements presented herein do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that we cannot continue as a going concern.

~~The~~Our ability ~~Company~~to ~~sold the~~continue ~~140,000 Hukui~~as a going concern is dependent upon our ability to successfully execute our business plan and generate profitable ~~Shares~~operations ~~for~~in ~~$350~~the future,~~000 cash~~ onand, ~~November~~until 19and unless we achieve that, ~~2021.~~to ~~The~~obtain ~~proceeds~~the ~~will~~necessary befinancing ~~used~~to ~~for~~meet ~~operational~~our ~~expenses~~obligations and repay our liabilities arising from normal business operation as and when they become due. ~~Management~~To ~~believes~~date, ~~that~~our ~~these funds~~capital ~~are~~requirements ~~sufficient~~have toprimarily ~~fund~~been funded by shareholders through the ~~Company’s~~purchase ~~expenses~~of ~~for~~our atCommon ~~least~~Stock ~~the~~in ~~next~~private 12offerings ~~months~~and short-term borrowings from a former officer and another shareholder.

~~Contractual~~The Company ~~Obligations~~sold the 140,000 Hukui Shares for $350,000 cash on November 19, 2021. The proceeds have been used for operation expenses.

~~We do not have material contractual obligations and commitments. We only have one lease that is renewed on a month-to-month basis.~~16

~~Off-Balance~~Contractual ~~Sheet Arrangements~~Obligations

~~As of June 30, 2022, we did~~We do not ~~enter~~have ~~into~~material ~~any~~contractual ~~other financial guarantees or other commitments to guarantee the payment~~ obligations ~~of any third parties. As of June 30, 2022, we did not enter into any derivative contracts that are indexed to our shares~~ and ~~classified as shareholder’s equity or that are not reflected in our condensed consolidated financial statements~~commitments. ~~Furthermore,~~We asonly ~~of June 30, 2022, we did not~~ have ~~any~~one ~~retained or~~lease ~~contingent interest in assets transferred to an unconsolidated entity~~ that ~~serves~~is asrenewed ~~credit,~~on ~~liquidity~~a ~~or market risk support~~ month-to-month ~~such entity~~basis. As of June 30, 2022, we did not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

~~Critical~~Off-Balance ~~accounting~~Sheet ~~policies and estimates~~Arrangements

~~Our discussion and analysis~~As of ~~our~~December ~~financial~~31, ~~condition~~2022, ~~and~~we ~~results~~had ofnot ~~operations~~entered ~~are~~into ~~based~~any ~~upon~~other ~~our condensed consolidated~~ financial ~~statements,~~guarantees ~~which~~or ~~have~~other ~~been~~commitments ~~prepared in~~to ~~accordance~~guarantee ~~with~~the ~~accounting~~payment ~~principles~~obligations of ~~generally~~any ~~accepted~~third ~~in the United States~~parties. ~~The~~As ~~preparation~~ of ~~these~~December ~~condensed~~31, ~~consolidated~~2022, ~~financial statements~~we ~~requires~~had usnot toentered ~~make~~into ~~estimates~~any ~~and~~derivative ~~judgments~~contracts that ~~affect~~are ~~the~~indexed ~~reported~~to ~~amounts~~our ofshares ~~assets, liabilities, revenues~~ and ~~expenses,~~classified ~~and~~as ~~related~~shareholder’s ~~disclosure~~equity ofor ~~contingent~~that ~~assets~~are ~~and~~not ~~liabilities.~~reflected Wein ~~continually evaluate~~ our ~~estimates,~~condensed ~~including~~consolidated ~~those~~financial ~~related~~statements. ~~to income taxes~~Furthermore, ~~and~~as ~~the valuation~~ of ~~equity transactions. We base our estimates on historical experience and on various other assumptions that~~December we31, ~~believed to be reasonable under the circumstances~~2022, ~~the~~we ~~results~~had ofnot ~~which~~had ~~form~~any ~~the~~retained ~~basis~~or ~~for~~contingent ~~making~~interest ~~judgments~~in ~~about the carrying values of~~ assets ~~and~~transferred ~~liabilities that are not readily apparent from other sources. Any future changes~~ to ~~these~~an ~~estimates~~unconsolidated ~~and~~entity ~~assumptions~~that ~~could cause~~serves aas ~~material change to our reported amounts of revenues~~credit, liquidity ~~expenses,~~or ~~assets~~market ~~and~~risk ~~liabilities.~~support ~~Actual~~to ~~results~~such ~~may differ from these estimates under different assumptions or conditions~~entity. ~~For~~As ~~the~~of ~~nine-month~~December ~~periods ended June 30~~31, 2022 ~~and 2021~~, nowe ~~significant~~had ~~estimates~~not ~~and~~had ~~assumptions have~~any ~~been~~variable ~~made~~interest in ~~the~~any ~~condensed~~unconsolidated ~~consolidated~~entity that ~~financial~~provides ~~statements.~~financing, ~~The~~liquidity, ~~following~~market ~~are~~risk ~~some~~or ofcredit ~~the~~support ~~critical accounting policies in relation~~ to ~~the~~us ~~preparation~~or ofengages ~~the~~in ~~condensed~~leasing, ~~consolidated~~hedging ~~financial~~or ~~statements.~~research ~~For~~and adevelopment ~~full summary of our critical accounting policies, please~~services ~~refer~~with ~~to Note 2 of Notes to Condensed Consolidated Financial Statements~~us.

~~Foreign~~Critical ~~currency~~accounting ~~translation~~policies and estimates

~~The~~Our discussion and analysis of our financial ~~statements~~condition and results of operations are based upon our ~~subsidiary~~condensed ~~denominated~~consolidated infinancial ~~currencies~~statements, which ~~other~~have ~~than~~been ~~the~~prepared ~~USD~~in ~~are~~accordance ~~translated~~with ~~into~~accounting ~~USD~~principles ~~using~~generally ~~the~~accepted ~~closing~~in ~~rate~~the ~~method~~United States. The ~~balance~~preparation ~~sheet~~of ~~items~~these condensed ~~are~~consolidated ~~translated~~financial ~~into~~statements ~~USD~~requires ~~using~~us to make estimates and judgments that affect the ~~exchange~~reported ~~rates~~amounts atof assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to income taxes, and the ~~respective~~valuation ~~balance~~of ~~sheet~~equity ~~dates~~transactions. ~~The~~We ~~capital~~base our estimates on historical experience and on various ~~reserves~~other assumptions ~~are~~that ~~translated at~~we ~~historical~~believed ~~exchange~~to ~~rates~~be ~~prevailing~~reasonable atunder the ~~time~~circumstances, the results of which form the ~~transactions~~basis ~~while~~for ~~income~~making judgments about the carrying values of assets and ~~expenses~~liabilities ~~items~~that are ~~translated~~not atreadily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. For the ~~average~~three months ended December 31, 2022 and 2021, no significant ~~exchange~~estimates ~~rate~~and ~~for~~assumptions have been made in the ~~period.~~condensed ~~All~~consolidated ~~exchange~~financial ~~differences~~statements. The following are ~~recorded~~some of the critical accounting policies in ~~stockholders’~~relation ~~equity~~to the preparation of the condensed consolidated financial statements. For a full summary of our critical accounting policies, please refer to Note 2 to the Condensed Consolidated Financial Statements.

~~Stock-Based~~Foreign ~~Compensation~~currency translation

WeThe financial ~~account~~statements ~~for~~of ~~stock-based compensation~~our subsidiary denominated in ~~which~~currencies weother ~~obtain~~than ~~employee~~the ~~services~~USD inare ~~share-based~~translated ~~payment~~into ~~transactions~~USD ~~under~~using ~~FASB~~the ~~ASC~~closing ~~Topic~~rate ~~718,~~method. The ~~Compensation~~balance –sheet ~~Stock Compensation,~~items ~~which~~are ~~requires~~translated usinto toUSD ~~expense~~using the ~~cost~~exchange ofrates ~~employee~~at ~~services~~the ~~received~~respective inbalance sheet dates. The capital and various reserves are translated at historical exchange ~~for~~rates anprevailing ~~award~~at the time of ~~equity~~the ~~instruments~~transactions ~~based~~while income and expenses items are translated onat the ~~grant~~average ~~date~~exchange ~~fair~~rate ~~value~~for ofthe ~~such~~period. ~~instruments~~All ~~over~~exchange ~~the~~differences ~~vesting~~are ~~period~~recorded in stockholders’ equity.

17Stock-Based Compensation

~~Recent~~We account ~~accounting~~for ~~pronouncements~~stock-based compensation in which we obtain employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires us to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

WeRecent ~~do not expect that the adoption of recently issued~~ accounting pronouncements will have a material impact on its financial position, results of operations, or cash flows. For a full summary of recent accounting pronouncements, please refer to Note 2 of Notes to Condensed Consolidated Financial Statements.

~~Currency~~We do ~~exchange~~not ~~rates~~expect that the adoption of recently issued accounting pronouncements will have a material impact on our financial position, results of operations, or cash flows. For a full summary of recent accounting pronouncements, please refer to Note 2 to the Condensed Consolidated Financial Statements.

~~Our~~Currency functional currency is the USD, and the functional currency of our operations is the TWD. It is anticipated that all of our sales will be denominated in TWD. As a result, changes in the relative values of USD and TWD affect our reported amounts of revenues and profit (or loss) as the results of our operations are translated into USD for reporting purposes. In particular, fluctuations in currency exchange rates could have a significant impact on our financial stability. Fluctuations in exchange rates between the USD and the TWD would also affect our gross and net profit margins and could result in foreign exchange and operating losses.

~~Our~~For financial ~~exposure~~reporting topurposes, ~~foreign~~the ~~exchange risk~~financial ~~primarily~~statements ~~relates~~of tothe ~~currency~~Company’s ~~gains~~Singapore orsubsidiary, ~~losses~~which ~~resulting~~are ~~from~~prepared ~~timing~~using ~~differences between~~ the ~~signing~~SGD, are oftranslated ~~sales~~into ~~contracts and~~ the ~~settling of~~Company’s ~~these~~reporting ~~contracts. Furthermore~~currency, weUSD. Assets ~~translate monetary assets~~ and liabilities ~~denominated~~are intranslated ~~other~~using ~~currencies~~the ~~into~~exchange ~~TWD,~~rate on the ~~functional currency~~balance ofsheet ~~our~~date, ~~operations.~~which ~~Our~~was ~~results~~0.7464 ~~of operations~~ and ~~cash~~0.6970 ~~flow~~as ~~are~~of ~~translated~~December at31, ~~average~~and ~~exchange~~September ~~rates~~30, ~~during~~2022, ~~the~~respectively. ~~period,~~Revenue and ~~assets and~~expenses ~~liabilities~~ are translated atusing ~~the~~average ~~unified~~ exchange ~~rate~~rates atprevailing ~~the~~during ~~end~~each ofreporting ~~the~~ period. ~~Translation adjustments resulting from this process~~ The 0.7214 and 0.7370 average ~~are~~exchange ~~included~~rates inwere ~~accumulated~~used ~~other~~to ~~comprehensive~~translate ~~income~~revenues inand ~~our~~expenses ~~statement~~for ofthe ~~shareholders’~~three ~~equity.~~months Weended ~~have~~December ~~not~~31, ~~used~~2022 ~~any~~and ~~forward contracts~~2021, ~~currency~~ ~~options~~respectively. orStockholders’ equity ~~borrowings~~is totranslated ~~hedge~~at ~~our~~historical ~~exposure to foreign currency~~ exchange ~~risk~~rates. WeAdjustments ~~cannot~~resulting ~~predict~~from the ~~impact~~translation ofare ~~future~~recorded ~~exchange rate~~as ~~fluctuations~~a onseparate ~~our~~component ~~results~~ of accumulated ~~operations~~other ~~and~~comprehensive ~~may~~loss ~~incur net foreign currency losses~~ in ~~the~~stockholders’ ~~future~~deficit.

To the extent that we hold assets denominated in USD, any appreciation of the TWD against the USD could result in a charge in our statement of operations and a reduction in the value of our USD-denominated assets. On the other hand, a decline in the value of the TWD against the USD could reduce the USD equivalent amounts of our financial results. 17

~~For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, USD~~ITEM 3. ~~Assets and liabilities~~ ~~are~~QUANTITATIVE ~~translated~~AND ~~using~~QUALITATIVE ~~the~~DISCLOSURE ~~exchange~~ABOUT ~~rate~~MARKET ~~on the balance sheet date, which was 0~~RISK.7195 and 0.7368 as of June 30, 2022 and September 30, 2021, respectively. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.7341 and 0.7480 average exchange rates were used to translate revenues and expenses for the nine months ended June 30, 2022 and 2021, respectively. Stockholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive loss in stockholders’ equity

18Not required for smaller reporting companies.

ITEM 3 4. CONTROLS ~~QUANTITATIVE~~ AND ~~QUALITATIVE DISCLOSURE ABOUT MARKET RISK~~PROCEDURES.

~~Not~~Evaluation of ~~required~~Disclosure ~~for~~Controls ~~smaller~~and ~~reporting companies.~~Procedures

~~ITEM~~Our disclosure 4controls and procedures are designed to ensure that the information relating to our Company, including our consolidated subsidiary, required to be disclosed in our reports filed with the Securities and Exchange Commission (the “SEC”) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow for timely decisions regarding required disclosure. We ~~CONTROLS~~conducted ~~AND~~an ~~PROCEDURES~~evaluation, under the supervision and with the participation of management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this annual report. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of the evaluation date, our disclosure controls and procedures were not effective due to material weaknesses in our internal control over financial reporting, as described below.

~~Evaluation~~Management’s Report ofon ~~Disclosure~~Internal ~~Controls~~Control ~~and~~Over ~~Procedures~~Financial Reporting

Our ~~disclosure controls and~~ ~~procedures~~management ~~are~~is ~~designed~~responsible tofor ~~ensure~~establishing ~~that~~and ~~the~~maintaining ~~information~~adequate ~~relating~~internal tocontrol ~~our~~over ~~Company~~financial reporting, ~~including~~as ~~our~~such ~~consolidated~~term ~~subsidiary,~~is ~~required to be~~defined ~~disclosed~~ in ~~our reports filed with the Securities and~~ Exchange ~~Commission~~Act Rules 13a-15(~~the “SEC”~~f) ~~is recorded, processed, summarized~~ and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow for timely decisions regarding required disclosure15d-15(f). ~~We conducted~~Under ~~an evaluation, under~~ the supervision and with the participation of management, including our chief executive officer and chief financial officer, ofwe ~~the~~conducted ~~effectiveness~~an evaluation of the design and ~~operation~~operating effectiveness of our ~~disclosure~~internal controls over ~~and~~financial ~~procedures~~reporting ~~(as~~based ~~defined~~on ~~in Rules 13a-15(e) and 15d-15(e) under~~ the ~~Securities~~framework ~~Exchange~~in ~~Act~~“Internal ofControl-Integrated ~~1934,~~Framework ~~as amended~~(2013)” asissued ofby the ~~end~~ Committee of ~~the~~Sponsoring ~~period~~Organizations ~~covered by this annual report. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as~~ of the ~~evaluation~~Treadway ~~date,~~Commission ~~our disclosure controls and procedures were not effective due to material weaknesses in our internal control over financial reporting, as described below~~(“COSO”).

~~Management’s~~Our internal ~~Report~~control onover ~~Internal~~financial ~~Control~~reporting includes those policies and procedures that (i) pertain to the maintenance of records that, ~~Over~~in ~~Financial~~reasonable ~~Reporting~~detail, accurately and fairly reflect the transactions and dispositions of the assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements.

~~Our management is responsible~~Management ~~for~~assessed ~~establishing~~the ~~and~~effectiveness ~~maintaining~~of ~~adequate~~the Company’s internal control over financial reporting, as ~~such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation~~ of ~~management,~~December ~~including our chief executive officer and chief financial officer~~31, we2022 ~~conducted an evaluation of the design~~ and ~~operating~~identified ~~effectiveness of our internal controls over financial reporting based on~~ the ~~framework in “Internal Control-Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of~~ ~~the~~following ~~Treadway~~material ~~Commission (“COSO”).~~weaknesses:

~~Our internal control over financial~~Inadequate ~~reporting~~Segregation ~~includes those policies and procedures that (i) pertain to the maintenance~~ of ~~records~~Duties: ~~that,~~We inhave ~~reasonable~~an ~~detail,~~inadequate ~~accurately and~~number ~~fairly reflect the transactions and dispositions~~ of ~~the~~personnel ~~assets; (ii) provide reasonable assurance that transactions are recorded as necessary~~ to ~~permit~~properly ~~preparation~~implement ofcontrol consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statementsprocedures.

~~Management~~Comingling of ~~assessed~~funds: ~~the~~We ~~effectiveness of~~do ~~the~~not ~~Company’s~~have ~~internal~~adequate control ~~over~~of ~~financial~~our ~~reporting~~petty ascash, resulting in the comingling of ~~June~~our ~~30,~~petty ~~2022 and~~cash ~~identified~~with the ~~following~~nominal ~~material~~account holder’s ~~weaknesses:~~personal funds.

~~Inadequate~~Lack of ~~Segregation~~Adequate ~~of Duties~~Staffing: We ~~have~~do annot ~~inadequate~~have ~~number~~adequate ofin-house accounting personnel toand ~~properly~~expertise ~~implement~~in ~~control~~key ~~procedures~~positions, which resulted in overly relying on outside consultants in preparing financial statements and other required disclosures by the Securities and Exchange Commission.

~~Comingling of funds~~Ineffective oversight: We do not ~~have~~exercise ~~adequate~~effective ~~control~~oversight ofand ~~our~~monitoring ~~petty~~procedures ~~cash,~~designed ~~resulting~~and inimplemented ~~the~~to ~~comingling~~certain ofcontrol ~~our petty cash with the nominal account holder’s personal funds~~activities.

~~Lack~~Overly relied ofon ~~Adequate~~outside ~~Staffing~~professionals: We doare ~~not~~unable ~~have~~to ~~adequate~~prepare ~~in-house~~internally ~~accounting~~financial ~~personnel~~statements and ~~expertise~~relied ~~in key positions, which resulted in overly relying~~ on outside ~~consultants~~ inprofessional ~~preparing~~consultants to prepare financial statements and ~~other~~adequate ~~required~~ disclosures ~~by the Securities and Exchange Commission~~.

~~Ineffective oversight: We do not exercise effective oversight and monitoring procedures designed and implemented to certain control activities.~~18

~~Overly~~A material ~~relied~~weakness onis ~~outside~~a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is ~~professionals:~~a Wereasonable ~~are~~possibility ~~unable~~that toa ~~prepare~~material ~~internally~~misstatement of the Company’s annual or interim financial statements ~~and~~will ~~relied~~not be prevented or detected on ~~outside~~a ~~professional~~timely ~~consultants~~basis. toAs ~~prepare~~a result of the material weaknesses in internal control over financial reporting identified above, management concluded that the Company’s internal control over financial ~~statements~~reporting ~~and~~was ~~adequate~~not ~~disclosures~~effective as of December 31, 2022 based on the criteria set forth in “Internal Control-Integrated Framework” issued by COSO.

19Due to the nature of the material weaknesses, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected. The material weaknesses identified above either individually or in aggregation did not result in any identified misstatements or errors in the Company’s condensed consolidated financial statements at and for the three-month periods ended December 31, 2022.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the CompanyManagement’s ~~annual or interim financial statements will not be prevented or detected on a timely basis. As a result~~ ofPlan ~~the~~for material weaknesses in internal control over financial reporting identified above, management concluded that the Company’s internal control over financial reporting was not effective as of June 30, 2022 based on the criteria set forth in “Internal Control-Integrated Framework” issued by COSO.Remediation

~~Due to the nature of the material~~Management ~~weaknesses,~~has ~~there~~discussed ~~is a more than remote likelihood that misstatements which could be material to~~ the ~~annual or interim financial statements could occur that would not be prevented or detected. The~~ material weaknesses ~~identified~~noted above ~~either~~with ~~individually~~our orindependent inregistered ~~aggregation~~public ~~did not~~accounting ~~result~~firm. inManagement ~~any~~is ~~identified~~committed ~~misstatements~~to improving orits ~~errors~~internal incontrols ~~the Company’s condensed consolidated financial statements at~~ and, ~~for~~subject ~~the nine-month~~to ~~periods~~having ~~ended~~adequate ~~June~~financial 30resources, ~~2022.~~intends to:

~~Management’s~~● ~~Plan~~increase ~~for~~the ~~Remediation~~frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties to monitor and review until there are sufficient personnel to segregate duties;

~~Management~~● ~~has~~consider ~~discussed~~providing ~~the material~~professional ~~weaknesses~~courses ~~noted~~for ~~above with~~ our ~~independent~~key ~~registered~~position ~~public accounting firm. Management is committed to improving its internal controls and, subject to having adequate financial resources, intends to:~~personnel;

● ~~increase~~hire ~~the~~additional ~~frequency~~employees ofto ~~independent~~realize ~~reconciliations of significant accounts which will mitigate the lack of~~ segregation of duties; ~~to monitor~~ and ~~review until there are sufficient personnel to segregate duties;~~

● ~~consider~~strengthen ~~providing~~management ~~professional~~monitoring ~~courses~~control ~~for~~over ~~our~~accounting ~~key~~and ~~position~~financial ~~personnel;~~statements preparation processing.

●However, due ~~hire~~to ~~additional~~limitation ~~employees~~of funds and personnel, we have so far been unable to ~~realize~~begin ~~segregation~~to ofimplement ~~duties;~~the plan to remediate the material weaknesses noted above and it is uncertain when we will be able to begin to implement the plan to remediate these material weaknesses.

●Inherent Limitations ~~strengthen~~on ~~management~~Effectiveness ~~monitoring~~of ~~control over accounting and financial statements preparation processing.~~Controls

~~However~~A control system, ~~due~~no tomatter ~~limitation~~how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of ~~funds~~its ~~and~~inherent ~~personnel~~limitations, weinternal ~~have~~control soover ~~far~~financial ~~been~~reporting ~~unable~~may tonot ~~begin~~prevent toor ~~implement~~detect ~~the~~all control ~~plan~~issues or misstatements. Accordingly, our controls and procedures are designed to ~~remediate~~provide reasonable, not absolute, assurance that the ~~material~~objectives ~~weaknesses~~of ~~noted~~our ~~above~~control ~~and it~~system isare ~~uncertain~~met. ~~when~~Projections weof ~~will~~any beevaluation ~~able~~of effectiveness to ~~begin~~future periods are subject to ~~implement~~the risk that controls may become adequate because of changes in conditions, or that the ~~plan~~degree toof ~~remediate~~compliance ~~these~~with ~~material~~the ~~weaknesses~~policies or procedures may deteriorate.

~~Inherent~~Changes in ~~Limitations~~Internal ~~on Effectiveness of Controls~~Control

AThere have ~~control~~been ~~system,~~ no ~~matter how~~changes ~~well~~in ~~designed~~our ~~and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of its inherent limitations,~~ internal control over financial reporting ~~may~~that ~~not~~occurred ~~prevent~~during ~~or detect all control issues or misstatements. Accordingly, our controls and procedures are designed to provide reasonable, not absolute, assurance that~~ the ~~objectives~~period ofcovered ~~our~~by ~~control system~~this ~~are~~report ~~met. Projections of any evaluation of effectiveness to future periods are subject to the risk~~ that ~~controls may become adequate~~have ~~because~~materially ~~of changes in conditions~~affected, or ~~that~~are ~~the~~reasonably ~~degree~~likely ofto ~~compliance~~materially ~~with~~affect, ~~the~~our ~~policies~~internal orcontrol ~~procedures~~over ~~may~~financial ~~deteriorate~~reporting.

~~Changes in Internal Control~~19

~~There have been no changes~~PART in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.II

20OTHER INFORMATION

~~PART~~ITEM 1. LEGAL IIPROCEEDINGS

~~OTHER~~We ~~INFORMATION~~are not currently a party to any lawsuit or proceeding, which, in the opinion of management, is likely to have a material adverse effect on us or our business.

ITEM 1 1A. RISK ~~LEGAL PROCEEDINGS~~FACTORS

~~We are not currently a party~~Not torequired ~~any lawsuit or proceeding, which, in the opinion~~ of ~~management,~~smaller isreporting ~~likely to have a material adverse effect on us or our business~~companies.

ITEM 1A 2. UNREGISTERED ~~RISK~~SALES ~~FACTORS~~OF EQUITY SECURITIES AND USE OF PROCEEDS

~~Not required of smaller reporting companies~~None.

ITEM 2 3. DEFAULTS ~~UNREGISTERED~~UPON ~~SALES~~SENIOR ~~OF EQUITY~~ SECURITIES ~~AND USE OF PROCEEDS~~

None.

ITEM 3 4. MINE ~~DEFAULTS~~SAFETY ~~UPON SENIOR SECURITIES~~DISCLOSURES

~~None~~Not applicable.

ITEM 4 5. OTHER ~~MINE SAFETY DISCLOSURES~~INFORMATION

~~Not applicable~~None.

~~ITEM 5. OTHER INFORMATION~~20

~~None~~ITEM 6. EXHIBITS

Exhibit No.		Description
31.1		Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.
31.2		Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.
32.1*		Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*		Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

~~ITEM~~* 6The certifications attached as Exhibits 32.1 ~~EXHIBITS~~and 32.2 accompany this quarterly report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

Exhibit No.		Description
31.1		Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.
31.2		Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934.
32.1*		Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*		Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* The certifications attached as Exhibits 32.1 and 32.2 accompany this quarterly report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.SIGNATURES

22Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SIGNATURES

	GENUFOOD ENERGY ENZYMES CORP.

Date: February 14, 2023	By:	/s/ David Tang
		David Tang
		Chief Executive Officer

	By:	/s/ Shao-Cheng Wang
		Shao-Cheng Wang
		Chief Financial Officer

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.22

	GENUFOOD ENERGY ENZYMES CORP.
Date: August 12, 2022	By:	/s/ David Tang
		David Tang
		Chief Executive Officer
	By:	/s/ Shao-Cheng Wang
		Shao-Cheng Wang
		Chief Financial Officer

NONE Yes 68-0681158 Yes 299686921 299686921 false --09-30 Q1 2023 false 0001510518 0001510518 2022-10-01 2022-12-31 0001510518 2023-02-13 0001510518 2022-12-31 0001510518 2022-09-30 0001510518 2021-10-01 2021-12-31 0001510518 us-gaap:CommonStockMember 2022-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-09-30 0001510518 us-gaap:RetainedEarningsMember 2022-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001510518 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2022-10-01 2022-12-31 0001510518 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2022-12-31 0001510518 us-gaap:CommonStockMember 2022-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2022-12-31 0001510518 us-gaap:RetainedEarningsMember 2022-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001510518 us-gaap:CommonStockMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001510518 2021-09-30 0001510518 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2021-10-01 2021-12-31 0001510518 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2021-12-31 0001510518 us-gaap:CommonStockMember 2021-12-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001510518 gfoo:DiscountOnCommonStockMember 2021-12-31 0001510518 us-gaap:RetainedEarningsMember 2021-12-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001510518 2021-12-31 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-01 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-01 2021-06-25 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 gfoo:HukuiBiotechnologyCorporationMember 2021-11-19 0001510518 2021-11-10 2021-11-19 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-01 2020-09-23 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-23 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 2021-11-01 2021-11-19 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-01 2022-07-15 0001510518 srt:ChiefExecutiveOfficerMember 2022-07-15 0001510518 2021-10-01 2022-09-30 0001510518 us-gaap:StockOptionMember 2021-10-01 2022-09-30 0001510518 us-gaap:StockOptionMember 2022-10-01 2022-12-31 0001510518 2020-10-01 2021-09-30 0001510518 gfoo:YiLungOliverLinMember 2022-10-01 2022-12-31 0001510518 gfoo:JuiPinJohnLinMember 2022-10-01 2022-12-31 0001510518 gfoo:JiaTianJefferyLinMember 2022-10-01 2022-12-31 0001510518 gfoo:WenPiaoJackLaiMember 2022-10-01 2022-12-31 0001510518 gfoo:ShaoChengWillWangMember 2022-10-01 2022-12-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-10-01 2022-12-31 0001510518 gfoo:NanYaoJakeChanMember 2022-10-01 2022-12-31 0001510518 gfoo:HsinTaDarrenSuMember 2022-10-01 2022-12-31 0001510518 gfoo:HuiChuanSandraLinMember 2022-10-01 2022-12-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-12-31 0001510518 gfoo:KuangMingJamesTsaiMember 2022-09-30 0001510518 gfoo:JuiPinJohnLinMember 2022-12-31 0001510518 gfoo:JuiPinJohnLinMember 2022-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2022-12-31 0001510518 gfoo:JiaTianJefferyLinMember 2022-09-30 0001510518 gfoo:ShaoChengWillWangMember 2022-12-31 0001510518 gfoo:ShaoChengWillWangMember 2022-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2022-12-31 0001510518 gfoo:WenPiaoJackLaiMember 2022-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2022-12-31 0001510518 gfoo:HsinTaDarrenSuMember 2022-09-30 0001510518 gfoo:HuiChuanSandraLinMember 2022-12-31 0001510518 gfoo:HuiChuanSandraLinMember 2022-09-30 0001510518 gfoo:NaoYaoJakeChanMember 2022-12-31 0001510518 gfoo:NaoYaoJakeChanMember 2022-09-30 0001510518 2019-10-01 2020-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Yes Yes 189356789 230622703 299686921 299686921 false --09-30 Q3 false 0001510518 00-0000000 0001510518 2021-10-01 2022-06-30 0001510518 2022-08-10 0001510518 2022-06-30 0001510518 2021-09-30 0001510518 2022-04-01 2022-06-30 0001510518 2021-04-01 2021-06-30 0001510518 2020-10-01 2021-06-30 0001510518 us-gaap:CommonStockMember 2022-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001510518 gfoo:DiscountOnCommonStockMember 2022-03-31 0001510518 us-gaap:RetainedEarningsMember 2022-03-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001510518 2022-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-04-01 2022-06-30 0001510518 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001510518 us-gaap:CommonStockMember 2022-06-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001510518 gfoo:DiscountOnCommonStockMember 2022-06-30 0001510518 us-gaap:RetainedEarningsMember 2022-06-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001510518 us-gaap:CommonStockMember 2021-03-31 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001510518 gfoo:DiscountOnCommonStockMember 2021-03-31 0001510518 us-gaap:RetainedEarningsMember 2021-03-31 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001510518 2021-03-31 0001510518 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-04-01 2021-06-30 0001510518 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001510518 us-gaap:CommonStockMember 2021-06-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-06-30 0001510518 us-gaap:RetainedEarningsMember 2021-06-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001510518 2021-06-30 0001510518 us-gaap:CommonStockMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-09-30 0001510518 us-gaap:RetainedEarningsMember 2021-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-06-30 0001510518 gfoo:DiscountOnCommonStockMember 2021-10-01 2022-06-30 0001510518 us-gaap:RetainedEarningsMember 2021-10-01 2022-06-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-10-01 2022-06-30 0001510518 us-gaap:CommonStockMember 2020-09-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001510518 gfoo:DiscountOnCommonStockMember 2020-09-30 0001510518 us-gaap:RetainedEarningsMember 2020-09-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001510518 2020-09-30 0001510518 us-gaap:CommonStockMember 2020-10-01 2021-06-30 0001510518 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2021-06-30 0001510518 gfoo:DiscountOnCommonStockMember 2020-10-01 2021-06-30 0001510518 us-gaap:RetainedEarningsMember 2020-10-01 2021-06-30 0001510518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2021-06-30 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-01 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-01 2021-06-25 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-01 2021-11-17 0001510518 us-gaap:SeriesCPreferredStockMember 2021-11-17 0001510518 gfoo:HukuiBiotechnologyCorporationMember 2021-11-10 2021-11-19 0001510518 2021-11-10 2021-11-19 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-22 2020-09-23 0001510518 gfoo:HukuiAgreementMember us-gaap:SeriesCPreferredStockMember 2020-09-23 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2020-12-13 2020-12-15 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-22 2021-06-25 0001510518 us-gaap:SeriesCPreferredStockMember 2021-06-25 0001510518 gfoo:HukuiAgreementMember 2022-06-30 0001510518 gfoo:HukuiAgreementMember 2021-11-15 2021-11-17 0001510518 gfoo:HukuiAgreementMember 2021-11-17 0001510518 2021-11-15 2021-11-19 0001510518 gfoo:PrivateOfferingMember 2020-12-05 2020-12-15 0001510518 gfoo:PrivateOfferingMember 2020-12-15 0001510518 2020-10-01 2021-03-31 0001510518 us-gaap:CommonStockMember 2020-10-01 2021-03-31 0001510518 2020-10-01 2021-09-30 0001510518 2021-04-01 2021-04-09 0001510518 2021-04-09 0001510518 2021-06-15 0001510518 gfoo:PrivateOfferingMember 2021-06-15 0001510518 2021-06-01 2021-06-15 0001510518 2021-07-01 2021-07-15 0001510518 2021-07-15 0001510518 gfoo:YiLungOliverLinMember 2021-10-01 2022-06-30 0001510518 gfoo:JuiPinJohnLinMember 2021-10-01 2022-06-30 0001510518 gfoo:JiaTianJefferyLinMember 2021-10-01 2022-06-30 0001510518 gfoo:WenPiaoJackLaiMember 2021-10-01 2022-06-30 0001510518 gfoo:ShaoChengWillWangMember 2021-10-01 2022-06-30 0001510518 gfoo:KuangMingJamesTsaiMember 2021-10-01 2022-06-30 0001510518 gfoo:NanYaoJakeChanMember 2021-10-01 2022-06-30 0001510518 gfoo:HsinTaDarrenSuMember 2021-10-01 2022-06-30 0001510518 gfoo:KuangMingJamesTsaiMember 2022-06-30 0001510518 gfoo:KuangMingJamesTsaiMember 2021-09-30 0001510518 gfoo:JuiPinJohnLinMember 2022-06-30 0001510518 gfoo:JuiPinJohnLinMember 2021-09-30 0001510518 gfoo:JiaTianJefferyLinMember 2022-06-30 0001510518 gfoo:JiaTianJefferyLinMember 2021-09-30 0001510518 gfoo:ShaoChengWillWangMember 2022-06-30 0001510518 gfoo:ShaoChengWillWangMember 2021-09-30 0001510518 gfoo:WenPiaoJackLaiMember 2022-06-30 0001510518 gfoo:WenPiaoJackLaiMember 2021-09-30 0001510518 gfoo:HsinTaDarrenSuMember 2022-06-30 0001510518 gfoo:HsinTaDarrenSuMember 2021-09-30 0001510518 2022-06-01 2022-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Filing Compare · Genufood Energy Enzymes Corp.